

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Rituximab therapy in pemphigus and other... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-83/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-83" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Rituximab therapy in pemphigus and other autoantibody-mediated diseases" />
    
            <meta name="og:title" content="F1000Research Article: Rituximab therapy in pemphigus and other autoantibody-mediated diseases.">
            <meta name="og:description" content="Read the latest article version by Nina A. Ran, Aimee S. Payne, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="10206">
            <meta name="article-id" content="9476">
            <meta name="dc.title" content="Rituximab therapy in pemphigus and other autoantibody-mediated diseases">
            <meta name="dc.description" content="Rituximab, a monoclonal antibody targeting the B cell marker CD20, was initially approved in 1997 by the United States Food and Drug Administration (FDA) for the treatment of non-Hodgkin lymphoma. Since that time, rituximab has been FDA-approved for rheumatoid arthritis and vasculitides such as granulomatosis with polyangiitis and microscopic polyangiitis. Additionally, rituximab has been used off-label in the treatment of numerous other autoimmune diseases, with notable success in pemphigus, an autoantibody-mediated skin blistering disease. The efficacy of rituximab therapy in pemphigus has spurred interest in its potential to treat other autoantibody-mediated diseases. This review summarizes the efficacy of rituximab in pemphigus and examines its off-label use in other select autoantibody-mediated diseases.">
            <meta name="dc.subject" content="Pemphigus, desmoglein, rituximab, autoantibody-mediated diseases, ">
            <meta name="dc.creator" content="Ran, Nina A.">
            <meta name="dc.creator" content="Payne, Aimee S.">
            <meta name="dc.date" content="2017/01/27">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.9476.1">
            <meta name="dc.source" content="F1000Research 2017 6:83">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Pemphigus ">
            <meta name="prism.keyword" content=" desmoglein ">
            <meta name="prism.keyword" content=" rituximab ">
            <meta name="prism.keyword" content=" autoantibody-mediated diseases ">
            <meta name="prism.keyword" content=" ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/01/27">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="83">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.9476.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-83">
            <meta name="citation_title" content="Rituximab therapy in pemphigus and other autoantibody-mediated diseases">
            <meta name="citation_abstract" content="Rituximab, a monoclonal antibody targeting the B cell marker CD20, was initially approved in 1997 by the United States Food and Drug Administration (FDA) for the treatment of non-Hodgkin lymphoma. Since that time, rituximab has been FDA-approved for rheumatoid arthritis and vasculitides such as granulomatosis with polyangiitis and microscopic polyangiitis. Additionally, rituximab has been used off-label in the treatment of numerous other autoimmune diseases, with notable success in pemphigus, an autoantibody-mediated skin blistering disease. The efficacy of rituximab therapy in pemphigus has spurred interest in its potential to treat other autoantibody-mediated diseases. This review summarizes the efficacy of rituximab in pemphigus and examines its off-label use in other select autoantibody-mediated diseases.">
            <meta name="citation_description" content="Rituximab, a monoclonal antibody targeting the B cell marker CD20, was initially approved in 1997 by the United States Food and Drug Administration (FDA) for the treatment of non-Hodgkin lymphoma. Since that time, rituximab has been FDA-approved for rheumatoid arthritis and vasculitides such as granulomatosis with polyangiitis and microscopic polyangiitis. Additionally, rituximab has been used off-label in the treatment of numerous other autoimmune diseases, with notable success in pemphigus, an autoantibody-mediated skin blistering disease. The efficacy of rituximab therapy in pemphigus has spurred interest in its potential to treat other autoantibody-mediated diseases. This review summarizes the efficacy of rituximab in pemphigus and examines its off-label use in other select autoantibody-mediated diseases.">
            <meta name="citation_keywords" content="Pemphigus, desmoglein, rituximab, autoantibody-mediated diseases, ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Nina A. Ran">
            <meta name="citation_author_institution" content="Department of Dermatology, University of Pennsylvania, 1009 Biomedical Research Building, 421 Curie Boulevard, PA, USA">
            <meta name="citation_author" content="Aimee S. Payne">
            <meta name="citation_author_institution" content="Department of Dermatology, University of Pennsylvania, 1009 Biomedical Research Building, 421 Curie Boulevard, PA, USA">
            <meta name="citation_publication_date" content="2017/01/27">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="83">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.9476.1">
            <meta name="citation_firstpage" content="83">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-83/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-83.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=10206 /> <input type=hidden id=articleId name=articleId value=9476 /> <input type=hidden id=xmlUrl value="/articles/6-83/v1/xml"/> <input type=hidden id=xmlFileName value="-6-83-v1.xml"> <input type=hidden id=article_uuid value=b7cb8313-e027-4e43-93a7-2af5086c93e8 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Rituximab therapy in pemphigus and other autoantibody-mediated diseases"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.9476.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.9476.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-83"
  },
  "headline": "Rituximab therapy in pemphigus and other autoantibody-mediated diseases",
  "datePublished": "2017-01-27T16:29:05",
  "dateModified": "2017-01-27T16:29:05",
  "author": [
    {
      "@type": "Person",
      "name": "Nina A. Ran"
    },    {
      "@type": "Person",
      "name": "Aimee S. Payne"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Rituximab, a monoclonal antibody targeting the B cell marker CD20, was initially approved in 1997 by the United States Food and Drug Administration (FDA) for the treatment of non-Hodgkin lymphoma. Since that time, rituximab has been FDA-approved for rheumatoid arthritis and vasculitides such as granulomatosis with polyangiitis and microscopic polyangiitis. Additionally, rituximab has been used off-label in the treatment of numerous other autoimmune diseases, with notable success in pemphigus, an autoantibody-mediated skin blistering disease. The efficacy of rituximab therapy in pemphigus has spurred interest in its potential to treat other autoantibody-mediated diseases. This review summarizes the efficacy of rituximab in pemphigus and examines its off-label use in other select autoantibody-mediated diseases."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-83/v1",
            "name": "Rituximab therapy in pemphigus and other autoantibody-mediated diseases"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Rituximab therapy in pemphigus and other autoantibody-mediated diseases </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=10206 data-id=9476 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9476.1" data-recommended="" data-doi="10.12688/f1000research.9476.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-83/v1/pdf?article_uuid=b7cb8313-e027-4e43-93a7-2af5086c93e8" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-9476-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-9476-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-9476-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Ran NA and Payne AS. Rituximab therapy in pemphigus and other autoantibody-mediated diseases [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):83 (<a class=new-orange href="https://doi.org/10.12688/f1000research.9476.1" target=_blank>https://doi.org/10.12688/f1000research.9476.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-9476-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=9476 id=track-article-signin-9476 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9476?target=/articles/6-83/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10206 /> <input name=articleId type=hidden value=9476 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Rituximab therapy in pemphigus and other autoantibody-mediated diseases</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Nina A. Ran,&nbsp;</span><span class=""><a href="mailto:paynea@mail.med.upenn.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Aimee S. Payne</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Nina A. Ran,&nbsp;</span><span class=""><a href="mailto:paynea@mail.med.upenn.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Aimee S. Payne</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 27 Jan 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.9476.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Dermatology, University of Pennsylvania, 1009 Biomedical Research Building, 421 Curie Boulevard, PA, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=20008-19669></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=20005-19667></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=20006-19668></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Rituximab, a monoclonal antibody targeting the B cell marker CD20, was initially approved in 1997 by the United States Food and Drug Administration (FDA) for the treatment of non-Hodgkin lymphoma. Since that time, rituximab has been FDA-approved for rheumatoid arthritis and vasculitides such as granulomatosis with polyangiitis and microscopic polyangiitis. Additionally, rituximab has been used off-label in the treatment of numerous other autoimmune diseases, with notable success in pemphigus, an autoantibody-mediated skin blistering disease. The efficacy of rituximab therapy in pemphigus has spurred interest in its potential to treat other autoantibody-mediated diseases. This review summarizes the efficacy of rituximab in pemphigus and examines its off-label use in other select autoantibody-mediated diseases. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Pemphigus, desmoglein, rituximab, autoantibody-mediated diseases, </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Aimee S. Payne (<a href="mailto:paynea@mail.med.upenn.edu">paynea@mail.med.upenn.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Aimee S. Payne </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Aimee Payne has served as a consultant for Syntimmune and TG Therapeutics. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number TL1TR001880 (NAR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. <br/> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Ran NA and Payne AS. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Ran NA and Payne AS. Rituximab therapy in pemphigus and other autoantibody-mediated diseases [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):83 (<a href="https://doi.org/10.12688/f1000research.9476.1" target=_blank>https://doi.org/10.12688/f1000research.9476.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 27 Jan 2017, <b>6</b>(F1000 Faculty Rev):83 (<a href="https://doi.org/10.12688/f1000research.9476.1" target=_blank>https://doi.org/10.12688/f1000research.9476.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 27 Jan 2017, <b>6</b>(F1000 Faculty Rev):83 (<a href="https://doi.org/10.12688/f1000research.9476.1" target=_blank>https://doi.org/10.12688/f1000research.9476.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d70223e155>Introduction</h2><p class="" id=d70223e158>Autoimmunity occurs when the body’s immune system mistakenly attacks self rather than foreign pathogens, leading to end-organ damage. B cells play a role in autoimmunity through several potential mechanisms, including antigen presentation, regulation of inflammation, and production of autoantibodies. These autoantibodies directly cause disease in several disorders, including pemphigus.</p><p class="" id=d70223e161>The critical role of B cells in autoimmune disorders has prompted interest in the use of B-cell-depleting therapies such as rituximab, a chimeric monoclonal antibody against the B cell surface antigen CD20. Of note, rituximab has striking efficacy in pemphigus, a finding mostly attributed to the central role of autoreactive B cells and autoantibodies in this disease. Rituximab has also been shown to downregulate autoreactive T helper cells in pemphigus patients, either by reducing B-cell-mediated antigen presentation or through direct depletion of CD20<sup>+</sup> T cells; the latter has been identified at similar rare frequencies in patients with multiple sclerosis and rheumatoid arthritis and in healthy individuals although their pathophysiologic significance to disease onset and remission after rituximab remains unclear<sup><a href="#ref-1">1</a>–<a href="#ref-3">3</a></sup>. Nevertheless, the success of rituximab in pemphigus invites a reappraisal of its therapeutic efficacy in other autoantibody-mediated diseases. This review uses pemphigus as a paradigm to discuss the pathophysiology of select autoantibody-mediated diseases and to evaluate the role of rituximab in their treatment.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d70223e177>Pemphigus: a paradigm for autoantibody-mediated diseases</h2><p class="" id=d70223e180>In pemphigus, autoantibodies to desmoglein (Dsg) skin cell adhesion proteins cause potentially severe epithelial blistering<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>, which can lead to death from malnutrition, dehydration, and infection. There are two major subtypes of pemphigus: pemphigus vulgaris (PV), which is characterized by autoantibodies to Dsg3, and pemphigus foliaceus (PF), characterized by autoantibodies to Dsg1.</p><p class="" id=d70223e190>Laboratory studies and clinical observations have established that the anti-Dsg antibodies in pemphigus sera are by themselves the disease-causing agents. Dsg1 and Dsg3 ELISAs have high sensitivity and specificity (98–100%) for disease, indicating that pemphigus does not occur in the absence of anti-Dsg antibodies and, furthermore, disease activity correlates with serum autoantibody titer<sup><a href="#ref-6">6</a>–<a href="#ref-8">8</a></sup>. Direct evidence for the pathogenicity of anti-Dsg antibodies comes from early observations that transplacental transfer of autoantibodies from mothers with PV leads to neonatal pemphigus<sup><a href="#ref-9">9</a>–<a href="#ref-12">12</a></sup>. Definitive evidence derives from experiments showing that affinity purified anti-Dsg antibodies as well as recombinant monoclonal anti-Dsg antibodies cause characteristic pemphigus skin blisters<sup><a href="#ref-13">13</a>–<a href="#ref-18">18</a></sup> and conversely that removal of anti-Dsg antibodies from pemphigus serum abolishes its pathogenicity<sup><a href="#ref-19">19</a>,<a href="#ref-20">20</a></sup>. Moreover, anti-Dsg autoantibodies cause blister formation in human skin and animal models even as monovalent antibody fragments<sup><a href="#ref-15">15</a>,<a href="#ref-17">17</a>,<a href="#ref-21">21</a>,<a href="#ref-22">22</a></sup>, indicating that antigen cross-linking or Fc-mediated functions are not required for pathogenicity, even though such mechanisms can contribute to blister formation<sup><a href="#ref-23">23</a></sup>. Autoimmunity against other antigens in pemphigus has also been described<sup><a href="#ref-24">24</a>–<a href="#ref-28">28</a></sup>. Regardless, these data collectively and definitively establish pemphigus as an autoantibody-mediated, not just an autoantibody-associated, disease. This conclusion spurs the rationale for evaluating the efficacy of B-cell-depleting agents in pemphigus.</p><div class=section><a name=d70223e246 class=n-a></a><h3 class=section-title>Efficacy of rituximab in pemphigus</h3><p class="" id=d70223e251>Rituximab has emerged as an effective therapeutic option for pemphigus patients. Nearly all patients (95–100%) experience initial disease control<sup><a href="#ref-29">29</a>,<a href="#ref-30">30</a></sup>. A recent meta-analysis of 578 cases showed a complete remission (CR) rate of 76% after rituximab<sup><a href="#ref-31">31</a></sup>, which included patients remaining on systemic immunosuppressive therapies; CR rates of 100% and 59% were reported in prospective studies, with the latter using a more stringent definition of CR<sup><a href="#ref-30">30</a>,<a href="#ref-32">32</a></sup>. The rate of relapse generally increases with length of clinical follow-up, ranging from 40–81%, with long-term rates of CR off therapy observed in 39–45% of patients<sup><a href="#ref-31">31</a>,<a href="#ref-32">32</a></sup>. One prospective study of rituximab and intravenous immunoglobulin (IVIg) in 11 patients reported 100% of patients achieving CR off therapy after long-term follow up<sup><a href="#ref-33">33</a></sup>.</p><p class="" id=d70223e283>The optimal dosing for rituximab in pemphigus has not been established. Because rituximab was initially approved for lymphoma, early pemphigus treatment protocols more often used the lymphoma dosing regimen (375 mg/m<sup>2</sup> weekly for four weeks). However, because the B cell burden in autoimmune disease is much lower than that in lymphoma, several studies have evaluated the RA regimen (two 1,000 mg doses given two weeks apart). A meta-analysis found no significant difference in CR rates between the two treatment regimens, although higher-dose protocols were associated with a significantly longer duration of disease remission<sup><a href="#ref-31">31</a></sup>. Additionally, relapse after rituximab has been shown to be associated with the same anti-Dsg B cells observed during active disease<sup><a href="#ref-34">34</a></sup>, indicating that relapse is due to incomplete B cell depletion; thus, higher-dose regimens that are more likely to achieve complete B cell depletion should offer the highest chance for long-term CR off therapy.</p><p class="" id=d70223e297>Several findings suggest the use of rituximab as a component of first-line therapy for disease. These include an association between disease duration prior to rituximab and rate of CR<sup><a href="#ref-35">35</a></sup>, as well as a 100% rate of long-term CR off therapy in five patients who received rituximab as first-line therapy<sup><a href="#ref-32">32</a></sup>. A randomized, open-label trial comparing rituximab and moderate-dose corticosteroids to high-dose corticosteroids as first-line therapy has recently completed, with study results pending publication (ClinicalTrials.gov ID: NCT00784589).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d70223e312>Other autoantibody-mediated diseases and the pemphigus paradigm</h2><p class="" id=d70223e315>Several other autoantibody-mediated diseases occur in humans. However, they may vary from the pemphigus paradigm in the diversity of autoantigens, the sensitivity and specificity of the autoantibodies, and the downstream effects of antibody binding. Nevertheless, an increasing number of studies have shown similarly promising results for the use of rituximab in many of these diseases, in particular neuromyelitis optica (NMO), thrombotic thrombocytopenic purpura (TTP), and myasthenia gravis (MG). The published literature includes a few hundred patients for each of these three diseases and has found notable improvements in remission and relapse rates. While randomized controlled trials are needed to confirm these initial findings, these three diseases represent areas of particular potential for B cell depletion strategies.</p><div class=section><a name=d70223e318 class=n-a></a><h3 class=section-title>Neuromyelitis optica</h3><p class="" id=d70223e323>NMO is characterized by inflammation, demyelination, and axonal injury to the spinal cord and optic nerve. The discovery that patients have antibodies against the astrocyte water channel aquaporin-4 (AQP4) helped distinguish NMO patients from those with multiple sclerosis<sup><a href="#ref-36">36</a>–<a href="#ref-38">38</a></sup>, and these antibodies are now a central part of NMO diagnosis<sup><a href="#ref-39">39</a></sup>. While the antibodies are nearly 100% specific, their sensitivity varies by assay and study (48–87%)<sup><a href="#ref-40">40</a>,<a href="#ref-41">41</a></sup>. Data have not consistently shown a correlation between antibody levels and disease activity or risk of relapse<sup><a href="#ref-42">42</a>,<a href="#ref-43">43</a></sup>. However, the findings of select studies suggest that anti-AQP4 antibodies may have prognostic value: antibody titers correlate with extent of transverse myelitis, antibody levels increase sharply before relapse in some patients, and positive titers during the initial episode of transverse myelitis may predict recurrent attacks<sup><a href="#ref-44">44</a>–<a href="#ref-46">46</a></sup>.</p><p class="" id=d70223e358>Strong support for the pathogenicity of anti-AQP4 antibodies comes from studies using monoclonal recombinant antibodies, purified antibodies, or patient serum<sup><a href="#ref-47">47</a>–<a href="#ref-50">50</a></sup>. Passive transfer of antibodies into mouse and rat experimental autoimmune encephalomyelitis (EAE) models exacerbates EAE symptoms and causes characteristic NMO lesions, including demyelination and/or loss of astrocytes with a decrease in astrocyte surface AQP4 expression in areas adjacent to astrocyte depletion. Removal of anti-AQP4 antibodies from patient sera markedly reduced the pathology<sup><a href="#ref-49">49</a></sup>. In addition, plasma exchange has been used with success in steroid-refractory NMO patients<sup><a href="#ref-51">51</a>–<a href="#ref-53">53</a></sup> and as first-line therapy<sup><a href="#ref-54">54</a></sup>. Still, several aspects of NMO pathogenesis require clarification, including whether anti-AQP4 antibodies are present in the central nervous system at the onset of disease. In addition, the observation that anti-AQP4 antibodies have produced pathology only in EAE models with prior T-cell-mediated inflammation has sparked interest in how the cellular immune response mediates disease<sup><a href="#ref-47">47</a>,<a href="#ref-49">49</a></sup>. A recent study found that transfer of anti-AQP4 reactive T cells into mice led to inflammatory infiltrate and demyelination, without the loss of astrocytes and AQP4 observed with antibody transfer<sup><a href="#ref-55">55</a></sup>; thus, the authors postulate that T cells may initiate and localize the autoimmune response as well as regulate downstream immune mediators including antibodies. Collectively, these data indicate that NMO antibodies are necessary for specific aspects of disease pathology, but the data supporting their sufficiency for disease induction have not been as clearly established.</p><p class="" id=d70223e395>Rituximab is commonly used to prevent relapse in NMO. Following a seminal study in eight patients<sup><a href="#ref-56">56</a></sup>, promising results have led to larger studies that have included more AQP4 IgG seropositive patients using a regimen of rituximab induction (either lymphoma or RA protocol) followed by maintenance infusions. The optimal rituximab maintenance strategy has not been established. Some studies used a fixed schedule (e.g. re-treatment every 6–9 months)<sup><a href="#ref-57">57</a>,<a href="#ref-58">58</a></sup> and chose to re-treat sooner if CD19<sup>+</sup> B cell count rose<sup><a href="#ref-59">59</a></sup>, while others re-treated based solely on memory B cell repletion<sup><a href="#ref-60">60</a></sup>. Studies with patients previously on other therapies found a 50–70% rate of relapse-free disease and a decrease in annualized relapse rate (ARR) of up to 96%<sup><a href="#ref-57">57</a>,<a href="#ref-59">59</a>–<a href="#ref-61">61</a></sup>. Rituximab has also been effective as initial therapy (84% rate of relapse-free disease; 97% reduction in ARR)<sup><a href="#ref-58">58</a></sup>, and the European Federation of Neurological Societies has recommended rituximab as first-line treatment for NMO<sup><a href="#ref-62">62</a></sup>.</p></div><div class=section><a name=d70223e440 class=n-a></a><h3 class=section-title>Thrombotic thrombocytopenic purpura</h3><p class="" id=d70223e445>TTP is a life-threatening thrombotic microangiopathy that arises when the metalloprotease ADAMTS13 does not cleave von Willebrand factor (vWF); this leads to the persistence of ultra-large vWF multimers that promote platelet aggregation and vessel occlusion. Acquired idiopathic TTP stems from autoantibodies against ADAMTS13. Inhibitory antibodies can prevent proteolysis by binding to the domain of ADAMTS13 that interacts with vWF<sup><a href="#ref-63">63</a>,<a href="#ref-64">64</a></sup>. More rarely, non-inhibitory antibodies that have no <i>in vitro</i> neutralization effect can still interfere with ADAMTS13 activity <i>in vivo</i> by promoting its clearance or preventing its binding to factors such as endothelial cells<sup><a href="#ref-65">65</a></sup>. Anti-ADAMTS13 antibodies have been detected in &gt;95% of patients with severely deficient ADAMTS13 levels (i.e. &lt;10% normal)<sup><a href="#ref-66">66</a>,<a href="#ref-67">67</a></sup>. However, the antibodies are less specific, as they have also been found in patients with systemic lupus erythematosus and anti-phospholipid antibody syndrome, as well as in healthy individuals<sup><a href="#ref-66">66</a>,<a href="#ref-68">68</a></sup>. Conflicting data exist regarding an association between antibody titer and disease course<sup><a href="#ref-69">69</a>–<a href="#ref-71">71</a></sup>.</p><p class="" id=d70223e487>Antibody pathogenicity was demonstrated by mouse monoclonal antibodies against ADAMTS13 that triggered TTP in baboons<sup><a href="#ref-72">72</a></sup>. New data also show that expression of inhibitory human single chain variable fragment (scFv) antibodies in mice results in features of TTP, further suggesting that antibody effect does not necessarily require Fc-mediated mechanisms<sup><a href="#ref-73">73</a></sup>. Additional support comes from the successful use of plasmapheresis to remove inhibitors and replace functional ADAMTS13, which is associated with an 80–90% survival rate and is used as standard first-line therapy<sup><a href="#ref-74">74</a>–<a href="#ref-76">76</a></sup>.</p><p class="" id=d70223e505>Rituximab has been used in roughly 250 TTP patients in the literature, either in refractory patients, as initial treatment, or during remission to prevent relapse<sup><a href="#ref-77">77</a></sup>. In a prospective study of 22 TTP patients with refractory disease, rituximab led to faster achievement of remission and higher rates of remission at 35 days (100%) compared to historic controls (78%)<sup><a href="#ref-78">78</a></sup>. While rituximab led to lower relapse rates at one year (0%) compared to controls (9%), the long-term relapse rate did not differ between the groups. When used in the initial treatment of acute TTP, rituximab led to lower relapse rates at one year compared to historic controls (0% vs. 16%), as well as during follow-up (11% vs. 55%), although the follow-up duration was longer in the control group<sup><a href="#ref-79">79</a></sup>. Lastly, studies have used rituximab maintenance dosing during remission to prevent relapse in patients with severe ADAMTS13 deficiency. In a recent cross-sectional study, those on rituximab had lower rates of relapse during the follow-up period (10%) compared to historic controls (39%), although follow-up for the controls was again longer. In general, rituximab is associated with an increase in ADAMTS13 activity and a decrease in inhibitor levels. Currently, rituximab is recommended for use in patients refractory to plasmapheresis and steroids and as initial treatment in severe forms of acute TTP<sup><a href="#ref-80">80</a></sup>.</p></div><div class=section><a name=d70223e525 class=n-a></a><h3 class=section-title>Myasthenia gravis</h3><p class="" id=d70223e530>MG was the first autoantibody-mediated neurologic disease to be discovered<sup><a href="#ref-81">81</a></sup>, and the disease has two main autoantigenic targets. Roughly 80–90% of patients have antibodies against the nicotinic acetylcholine receptor (AChR); these cause complement-mediated destruction<sup><a href="#ref-82">82</a>–<a href="#ref-85">85</a></sup>, crosslinking-induced activation and downregulation<sup><a href="#ref-86">86</a></sup>, or direct interference with ACh binding of the AChR<sup><a href="#ref-87">87</a></sup>, resulting in muscle fatigue and weakness. While autoantibody titers are not predictive of disease course<sup><a href="#ref-88">88</a></sup>, the causal role of autoantibodies has long been established: transplacental transfer of antibodies from mothers with myasthenia to the neonate can cause transient muscle weakness, and passive transfer of patient serum to mice leads to smaller miniature endplate potentials (MEPPs) and reduced AChR density<sup><a href="#ref-81">81</a>,<a href="#ref-89">89</a></sup>.</p><p class="" id=d70223e564>MG can also be caused by antibodies against muscle-specific receptor tyrosine kinase (MuSK), a transmembrane protein found on the post-synaptic membrane. Anti-MuSK antibodies are found in 40–70% of myasthenia patients lacking anti-AChR antibodies, although a lower prevalence has been observed in a few studies, particularly those in Asian ethnic groups<sup><a href="#ref-90">90</a>–<a href="#ref-92">92</a></sup>. As the antibodies are mostly IgG4 and do not fix complement, immune complexes are not found in the synapse<sup><a href="#ref-93">93</a>,<a href="#ref-94">94</a></sup>. Growing evidence has supported, though not firmly established, their pathogenic role. While muscle biopsies from MuSK-Ab-positive patients had smaller MEPPs, they did not show the reduction in AChR density or the striking synaptic structural changes observed in AChR-Ab-positive patients<sup><a href="#ref-94">94</a>,<a href="#ref-95">95</a></sup>. However, mice injected with purified anti-MuSK antibodies exhibit changes in synapse morphology (including reduced AChR density) and muscle weakness<sup><a href="#ref-96">96</a></sup>. In addition, the high success rate of plasma exchange in MuSK-Ab-positive patients supports a pathogenic role of the antibody<sup><a href="#ref-97">97</a></sup>.</p><p class="" id=d70223e596>Rituximab has been used in MG patients refractory to conventional immunosuppressive therapy. Roughly 200 MG patients have received rituximab in the literature, which predominantly consists of case reports and case series. Compared to AChR-Ab-positive patients, those with anti-MuSK antibodies have a higher response rate as well as more marked and sustained improvement<sup><a href="#ref-98">98</a>,<a href="#ref-99">99</a></sup>, leading investigators to propose that rituximab may have benefit earlier in the treatment of these patients<sup><a href="#ref-99">99</a></sup>. A recent meta-analysis showed an overall response rate of 84% and found non-significant differences in the response rates among anti-MuSK-positive patients (89%), anti-AChR-positive patients (80%), and double seronegative patients (86%)<sup><a href="#ref-100">100</a></sup>. The first double-blind randomized controlled trial of rituximab in anti-AChR-positive MG patients is ongoing (ClinicalTrials.gov ID: NCT02110706), and a second trial in patients with new onset, generalized MG is currently recruiting (ClinicalTrials.gov ID: NCT02950155).</p></div><div class=section><a name=d70223e616 class=n-a></a><h3 class=section-title>Graves’ disease</h3><p class="" id=d70223e621>Thyrotropin receptor autoantibodies (TRAb), or thyroid stimulating hormone receptor (TSHR) autoantibodies, play a critical role in autoimmune thyroid disease and are classified as stimulating, blocking, or neutral (although the latter has been shown to modulate downstream TSHR signaling). The hyperthyroidism characteristic of Graves’ disease is caused by stimulatory TRAb, which are observed in nearly all patients<sup><a href="#ref-101">101</a></sup>. While antibody levels decline with therapy, and while antibody persistence has been linked to a higher risk of relapse, TRAb level is not considered a reliable predictor of treatment response<sup><a href="#ref-102">102</a></sup>. The pathogenicity of TRAb has long been established by passive transfer experiments with patient serum, and by the ability of maternal autoantibodies to cause transient hyperthyroidism in the neonate<sup><a href="#ref-103">103</a>,<a href="#ref-104">104</a></sup>. Additional support comes from the recent isolation of two stimulatory human monoclonal TRAbs – M22 and K1-18. These have similar TSHR binding affinity as antibodies from patient sera, with thousands-fold greater potency. The Fab fragment of M22, but not of K1-18, has similar characteristics to the intact autoantibody<sup><a href="#ref-105">105</a>–<a href="#ref-107">107</a></sup>.</p><p class="" id=d70223e646>Case series and open-label studies of rituximab in Graves’ orbitopathy (GO) have shown a &gt;90% rate of disease inactivation<sup><a href="#ref-108">108</a></sup>. Two double-blind randomized controlled trials have been published to date, both in euthyroid patients with active, moderate-to-severe GO. The first study in 25 patients found no difference in clinical improvement between rituximab and placebo<sup><a href="#ref-109">109</a></sup>, while the second trial in 31 patients found greater clinical improvements with rituximab versus methylprednisolone<sup><a href="#ref-110">110</a></sup>. The authors of the second trial note that the discrepancy could be due to differences in the study populations, including number of patients, duration of disease, and prior steroid use. Still, in light of this inconsistency as well as previous data, rituximab is recommended as a second-line option for patients who are unresponsive to corticosteroids<sup><a href="#ref-111">111</a></sup>.</p></div><div class=section><a name=d70223e666 class=n-a></a><h3 class=section-title>Immune thrombocytopenic purpura</h3><p class="" id=d70223e671>Immune thrombocytopenic purpura (ITP) results from autoantibodies against multiple platelet surface proteins, including glycoproteins (GP)Ib/IX and GPIIa/IIIb, leading to platelet destruction<sup><a href="#ref-112">112</a>,<a href="#ref-113">113</a></sup>. Unlike pemphigus, anti-platelet antibodies have low sensitivity for the disease, with detection in roughly half of patients<sup><a href="#ref-114">114</a>–<a href="#ref-116">116</a></sup>. <i>In vitro</i> studies have shown that these antibodies bind complement, inhibit megakaryocytopoiesis, and hinder proplatelet formation<sup><a href="#ref-117">117</a>,<a href="#ref-118">118</a></sup>. Evidence of their pathogenicity stems from seminal studies in the 1950s and 1960s showing that transfer of plasma from ITP patients induced thrombocytopenia in human recipients without the disease<sup><a href="#ref-112">112</a>,<a href="#ref-119">119</a></sup>.</p><p class="" id=d70223e705>Following the first prospective study of rituximab in ITP in 2001<sup><a href="#ref-120">120</a></sup>, subsequent studies have indicated a complete response rate of 44% and an overall response rate of 63% (defined as platelet count &gt;150 and &gt;50 × 10<sup>9</sup> cells/L, respectively)<sup><a href="#ref-121">121</a></sup>; however, only 21–23% of patients have responses lasting five years<sup><a href="#ref-122">122</a>,<a href="#ref-123">123</a></sup>. One large randomized controlled trial in steroid-refractory patients compared rituximab to placebo with or without corticosteroids and found no difference in preventing the need for splenectomy<sup><a href="#ref-124">124</a></sup>. Similarly, a smaller pilot study examined rituximab versus placebo as adjuvants to standard care and found no difference in the composite endpoint of platelet count &lt;50 × 10<sup>9</sup>/L, significant bleeding, or need for rescue treatment<sup><a href="#ref-125">125</a></sup>. Recent efforts to improve therapeutic efficacy have included combining rituximab with other approved ITP therapies. Three randomized controlled trials show higher rates of sustained response with combined rituximab and steroids versus steroid therapy alone, suggesting an early role for rituximab in treatment<sup><a href="#ref-126">126</a>–<a href="#ref-128">128</a></sup>. A single-arm pilot study also investigated the addition of cyclosporine to this combination, which led to a response rate of 60% with remission persisting for longer than seven months<sup><a href="#ref-129">129</a></sup>. Alternative options such as adding recombinant human thrombopoietin to rituximab have also indicated potential benefit<sup><a href="#ref-130">130</a></sup>.</p></div><div class=section><a name=d70223e754 class=n-a></a><h3 class=section-title>Autoimmune hemolytic anemia</h3><p class="" id=d70223e759>In autoimmune hemolytic anemia (AIHA), the binding of antibodies to different antigens on the red blood cell (RBC) surface leads to RBC agglutination and lysis. Antibodies in warm AIHA are predominantly IgG, act at body temperature, and lead to both complement-mediated and Fc-dependent RBC destruction. In contrast, cold agglutinin disease (CAD) involves mainly IgM that bind at low temperature and result in complement-mediated RBC removal<sup><a href="#ref-131">131</a></sup>. The antibodies are highly sensitive and are required for disease diagnosis. Early demonstration of their pathogenicity came from studies on human erythrocytes sensitized with patient IgG or IgM and reintroduced into normal volunteers<sup><a href="#ref-132">132</a>,<a href="#ref-133">133</a></sup>. The role of plasma exchange in warm AIHA has not yet been established<sup><a href="#ref-134">134</a></sup>. In CAD, plasma exchange is considered a reasonable second-line option and is used in situations of elevated risk, including perioperatively and in cases of severe hemolysis<sup><a href="#ref-134">134</a>–<a href="#ref-136">136</a></sup>.</p><p class="" id=d70223e784>The literature in AIHA has, until recently, been limited to case reports and small prospective studies<i>,</i> with significant heterogeneity. A recent meta-analysis found an overall response rate of 73% and a complete response rate of 37%, though definitions of response differed by study<sup><a href="#ref-137">137</a></sup>. The overall and complete response rates were notably higher among warm AIHA patients (79% and 42%, respectively) compared to those with CAD (57% and 21%, respectively). Similar to studies in ITP, one open-label randomized controlled trial in warm AIHA showed that the combination of rituximab and prednisone led to a higher complete response rate at 12 months (75%) versus prednisone alone (36%), as well as a higher rate of relapse-free survival at 36 months<sup><a href="#ref-138">138</a></sup>.</p></div><div class=section><a name=d70223e799 class=n-a></a><h3 class=section-title>Anti-glomerular basement membrane disease</h3><p class="" id=d70223e804>In anti-glomerular basement membrane (GBM) disease, antibodies to the alpha 3 chain of collagen IV – α3(IV) – cause rapidly progressing glomerulonephritis and pulmonary hemorrhage (Goodpasture’s syndrome), glomerulonephritis alone, or, more rarely, isolated pulmonary hemorrhage<sup><a href="#ref-139">139</a>,<a href="#ref-140">140</a></sup>. These antibodies bind rapidly and tightly to the basement membrane with slow dissociation<sup><a href="#ref-141">141</a></sup>. Newer immunoassays have shown a sensitivity of 95–100% and specificity of 90–100%<sup><a href="#ref-142">142</a></sup>. Of note, anti-α3(IV) IgG are also found in healthy individuals, although these have lower titers, reduced affinity, and different IgG subclass composition compared to those isolated from patients<sup><a href="#ref-143">143</a></sup>. Given this finding, renal biopsy in addition to antibody screening is recommended to confirm diagnosis.</p><p class="" id=d70223e826>The pathogenicity of anti-α3(IV) antibodies was established by the demonstration that antibodies from patient serum and from nephritic kidneys induce rapid glomerulonephritis in squirrel monkeys<sup><a href="#ref-144">144</a></sup>. Currently, standard treatment involves the expedient use of plasmapheresis combined with cyclophosphamide and corticosteroids. The addition of plasmapheresis to initial therapy has led to striking improvements in survival (from &lt;20% to 65–100%), though response depends heavily on renal function at the initiation of therapy<sup><a href="#ref-145">145</a>,<a href="#ref-146">146</a></sup>.</p><p class="" id=d70223e840>Very few studies have been conducted on rituximab in anti-GBM disease. The largest case series included eight patients with severe and/or refractory disease<sup><a href="#ref-147">147</a></sup>. Seven patients achieved CR with no relapses, and rituximab was associated with a patient survival of 100%, a renal survival of 75%, and a disappearance of serum anti-GBM antibodies.</p></div><div class=section><a name=d70223e848 class=n-a></a><h3 class=section-title>Lambert-Eaton myasthenic syndrome</h3><p class="" id=d70223e853>In Lambert-Eaton myasthenic syndrome (LEMS), antibodies to voltage-gated calcium channels (VGCCs) on the presynaptic terminal reduce ACh release, leading to muscle weakness and autonomic symptoms. Antibodies to the P/Q-type of VGCC are found in 85–95% of patients; they have also been observed at a lower frequency in people with malignancy, amyotrophic lateral sclerosis, and other diseases<sup><a href="#ref-148">148</a>–<a href="#ref-150">150</a></sup>. Thus, the diagnosis of LEMS requires the consideration of electrophysiologic and clinical findings along with antibody presence. Passive transfer of purified anti-VGCC antibodies into mice reproduces the electrophysiological and morphologic changes found at the neuromuscular junction in LEMS patients<sup><a href="#ref-151">151</a>–<a href="#ref-153">153</a></sup>; moreover, decreased ACh release was observed in complement-deficient mice<sup><a href="#ref-154">154</a></sup>. The autoimmune origin of LEMS has prompted the sporadic use of plasmapheresis with immunosuppression, with varying responses<sup><a href="#ref-155">155</a>–<a href="#ref-158">158</a></sup>.</p><p class="" id=d70223e881>Data on rituximab in LEMS come from a very small number of case reports and case series<sup><a href="#ref-159">159</a>,<a href="#ref-160">160</a></sup>. Key findings were shown in a case series that included two patients with refractory disease, both with anti-VGCC antibodies<sup><a href="#ref-160">160</a></sup>. Both patients experienced improvement but not CR.</p></div><div class=section><a name=d70223e896 class=n-a></a><h3 class=section-title>Epidermolysis bullosa acquisita and bullous pemphigoid</h3><p class="" id=d70223e901>Epidermolysis bullosa acquisita (EBA) and bullous pemphigoid (BP) are subepithelial blistering diseases characterized by antibodies against different epithelial basement membrane zone antigens; specifically, EBA results from antibodies against type VII collagen (COL7), while BP arises from antibodies against BP antigen 180 (BP180, or COL17) or against BP230<sup><a href="#ref-161">161</a></sup>. For EBA, the COL7 ELISA is highly sensitive and specific (&gt;94%) in patients whose sera test positive with indirect immunofluorescence (IIF) to the dermal side of salt-split skin<sup><a href="#ref-162">162</a>–<a href="#ref-164">164</a></sup>. In patients with negative IIF on salt-split skin, the COL7 ELISA has high specificity (98%) but poor sensitivity (23%), leading the authors to recommend serration pattern analysis for this patient population<sup><a href="#ref-165">165</a></sup>. For BP, results of the BP180 and BP230 ELISA assays vary: most studies indicate a sensitivity and specificity of 70–98% and 90–100%, respectively, for the BP180 ELISA and 59–77% and 62–100%, respectively, for the BP230 ELISA<sup><a href="#ref-166">166</a>–<a href="#ref-171">171</a></sup>. Studies that compared the use of both the BP180 and the BP230 serologic assays to either assay alone found that the combined approach generally demonstrated improved sensitivity (87–100%) and similar specificity (88–90%) for disease diagnosis<sup><a href="#ref-166">166</a>,<a href="#ref-170">170</a>–<a href="#ref-172">172</a></sup>.</p><p class="" id=d70223e936>In both diseases, antibody titers correlate with disease activity<sup><a href="#ref-163">163</a>,<a href="#ref-173">173</a></sup>, and their pathogenicity is established. For EBA, rabbit IgG against murine COL7 recapitulate the EBA phenotype in mice, as do antibodies purified from patient sera. Of note, no blisters were observed with (Fab’)<sub>2</sub> fragments from these same antibodies or in complement-deficient mice, indicating a critical role for Fc-mediated processes<sup><a href="#ref-174">174</a>,<a href="#ref-175">175</a></sup>. Similarly, purified human anti-BP180 antibodies and recombinant human IgG1 anti-BP180 monoclonal antibodies lead to BP-like blisters in humanized BP180 mice<sup><a href="#ref-176">176</a>,<a href="#ref-177">177</a></sup>. Fab fragments not only fail to produce this phenotype but also protect mice against autoantibody-mediated blistering<sup><a href="#ref-178">178</a></sup>. Further support for the pathogenic role of antibodies in disease comes from the use of immunoadsorption to induce remission in recalcitrant EBA and BP<sup><a href="#ref-179">179</a>–<a href="#ref-182">182</a></sup>.</p><p class="" id=d70223e975>Small case series in BP patients have shown favorable results with rituximab in recalcitrant disease<sup><a href="#ref-183">183</a>–<a href="#ref-185">185</a></sup>, including a study of 12 patients receiving rituximab and IVIg who all achieved both clinical and serological remission<sup><a href="#ref-186">186</a></sup>. In addition, a study of 13 BP patients found a significantly higher rate of remission with the first-line use of rituximab and corticosteroids compared to steroids alone<sup><a href="#ref-187">187</a></sup>. Larger prospective studies are needed to confirm these early results.</p><p class="" id=d70223e993>Data on rituximab in EBA derive mainly from case reports, making estimates of treatment response challenging. Still, rituximab has shown promising results in a few patients with refractory disease<sup><a href="#ref-188">188</a>–<a href="#ref-193">193</a></sup>, either alone or in combination with immunoadsorption<sup><a href="#ref-179">179</a>,<a href="#ref-194">194</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d70223e1014>Summary</h2><p class="" id=d70223e1017>In conclusion, the use of rituximab has led to promising results in several autoantibody-mediated diseases. Larger studies including randomized controlled trials are needed to further evaluate its effectiveness, dosing, and placement in therapeutic algorithms. Looking forward, autoantibody-mediated diseases represent an area of great potential for rituximab and other B-cell-depleting therapies.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d70223e1 class=n-a></a><h2 class=main-title id=d70812>Competing interests</h2><p class=metadata-entry><a name=d70223e90 class=n-a></a><p id=d70223e92> Aimee Payne has served as a consultant for Syntimmune and TG Therapeutics.</p></p></div><div class=back-section><a name=d70223e1 class=n-a></a><h2 class=main-title id=d70814>Grant information</h2><p>This publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number TL1TR001880 (NAR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p></div><div class=back-section><a name=d70223e1024 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d71444>References</h2><div class="section ref-list"><a name=d70223e1024 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1124244"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e1031 class=n-a></a>Eming R, Nagel A, Wolff-Franke S, <i> et al.</i>: Rituximab exerts a dual effect in pemphigus vulgaris. <i>J Invest Dermatol.</i> 2008; <b>128</b>(12): 2850–8. <a target=xrefwindow id=d70223e1042 href="http://www.ncbi.nlm.nih.gov/pubmed/18563178">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1045 href="http://dx.doi.org/10.1038/jid.2008.172">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1124244">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718449387"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e1058 class=n-a></a>Palanichamy A, Jahn S, Nickles D, <i> et al.</i>: Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. <i>J Immunol.</i> 2014; <b>193</b>(2): 580–6. <a target=xrefwindow id=d70223e1069 href="http://www.ncbi.nlm.nih.gov/pubmed/24928997">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1072 href="http://dx.doi.org/10.4049/jimmunol.1400118">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1076 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4082756">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718449387">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d70223e1089 class=n-a></a>Wilk E, Witte T, Marquardt N, <i> et al.</i>: Depletion of functionally active CD20+ T cells by rituximab treatment. <i>Arthritis Rheum.</i> 2009; <b>60</b>(12): 3563–71. <a target=xrefwindow id=d70223e1100 href="http://www.ncbi.nlm.nih.gov/pubmed/19950291">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1103 href="http://dx.doi.org/10.1002/art.24998">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d70223e1112 class=n-a></a>Eyre RW, Stanley JR: Human autoantibodies against a desmosomal protein complex with a calcium-sensitive epitope are characteristic of pemphigus foliaceus patients. <i>J Exp Med.</i> 1987; <b>165</b>(6): 1719–24. <a target=xrefwindow id=d70223e1120 href="http://www.ncbi.nlm.nih.gov/pubmed/2438368">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1123 href="http://dx.doi.org/10.1084/jem.165.6.1719">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1126 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2188354">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d70223e1135 class=n-a></a>Amagai M, Klaus-Kovtun V, Stanley JR: Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. <i>Cell.</i> 1991; <b>67</b>(5): 869–77. <a target=xrefwindow id=d70223e1143 href="http://www.ncbi.nlm.nih.gov/pubmed/1720352">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1146 href="http://dx.doi.org/10.1016/0092-8674(91)90360-B">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d70223e1156 class=n-a></a>Amagai M, Komai A, Hashimoto T, <i> et al.</i>: Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. <i>Br J Dermatol.</i> 1999; <b>140</b>(6): 351–7. <a target=xrefwindow id=d70223e1167 href="http://www.ncbi.nlm.nih.gov/pubmed/10233237">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1170 href="http://dx.doi.org/10.1046/j.1365-2133.1999.02752.x">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d70223e1179 class=n-a></a>Cheng SW, Kobayashi M, Kinoshita-Kuroda K, <i> et al.</i>: Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. <i>Br J Dermatol.</i> 2002; <b>147</b>(2): 261–5. <a target=xrefwindow id=d70223e1190 href="http://www.ncbi.nlm.nih.gov/pubmed/12174096">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1193 href="http://dx.doi.org/10.1046/j.1365-2133.2002.04838.x">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d70223e1202 class=n-a></a>Schmidt E, Dahnrich C, Rosemann A, <i> et al.</i>: Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. <i>Exp Dermatol.</i> 2010; <b>19</b>(5): 458–63. <a target=xrefwindow id=d70223e1213 href="http://www.ncbi.nlm.nih.gov/pubmed/20163452">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1216 href="http://dx.doi.org/10.1111/j.1600-0625.2010.01069.x">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d70223e1225 class=n-a></a>Green D, Maize JC: Maternal pemphigus vulgaris with <i>in vivo</i> bound antibodies in the stillborn fetus. <i>J Am Acad Dermatol.</i> 1982; <b>7</b>(3): 388–92. <a target=xrefwindow id=d70223e1236 href="http://www.ncbi.nlm.nih.gov/pubmed/6890077">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1239 href="http://dx.doi.org/10.1016/S0190-9622(82)70125-2">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d70223e1248 class=n-a></a>Moncada B, Kettelsen S, Hernández-Moctezuma JL, <i> et al.</i>: Neonatal pemphigus vulgaris: role of passively transferred pemphigus antibodies. <i>Br J Dermatol.</i> 1982; <b>106</b>(4): 465–7. <a target=xrefwindow id=d70223e1259 href="http://www.ncbi.nlm.nih.gov/pubmed/7073971">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1262 href="http://dx.doi.org/10.1111/j.1365-2133.1982.tb04542.x">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d70223e1271 class=n-a></a>Wasserstrum N, Laros RK Jr: Transplacental transmission of pemphigus. <i>JAMA.</i> 1983; <b>249</b>(11): 1480–2. <a target=xrefwindow id=d70223e1279 href="http://www.ncbi.nlm.nih.gov/pubmed/6827727">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1282 href="http://dx.doi.org/10.1001/jama.1983.03330350056029">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d70223e1292 class=n-a></a>Hup JM, Bruinsma RA, Boersma ER, <i> et al.</i>: Neonatal pemphigus vulgaris: transplacental transmission of antibodies. <i>Pediatr Dermatol.</i> 1986; <b>3</b>(6): 468–72. <a target=xrefwindow id=d70223e1303 href="http://www.ncbi.nlm.nih.gov/pubmed/3550750">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1306 href="http://dx.doi.org/10.1111/j.1525-1470.1986.tb00653.x">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d70223e1315 class=n-a></a>Amagai M, Karpati S, Prussick R, <i> et al.</i>: Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. <i>J Clin Invest.</i> 1992; <b>90</b>(3): 919–26. <a target=xrefwindow id=d70223e1326 href="http://www.ncbi.nlm.nih.gov/pubmed/1522242">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1329 href="http://dx.doi.org/10.1172/JCI115968">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1333 href="http://www.ncbi.nlm.nih.gov/pmc/articles/329947">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d70223e1342 class=n-a></a>Ding X, Diaz LA, Fairley JA, <i> et al.</i>: The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic. <i>J Invest Dermatol.</i> 1999; <b>112</b>(5): 739–43. <a target=xrefwindow id=d70223e1353 href="http://www.ncbi.nlm.nih.gov/pubmed/10233765">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1356 href="http://dx.doi.org/10.1046/j.1523-1747.1999.00585.x">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d70223e1365 class=n-a></a>Payne AS, Ishii K, Kacir S, <i> et al.</i>: Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. <i>J Clin Invest.</i> 2005; <b>115</b>(4): 888–99. <a target=xrefwindow id=d70223e1376 href="http://www.ncbi.nlm.nih.gov/pubmed/15841178">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1379 href="http://dx.doi.org/10.1172/JCI24185">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1383 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1070425">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717970487"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e1392 class=n-a></a>Di Zenzo G, Di Lullo G, Corti D, <i> et al.</i>: Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface. <i>J Clin Invest.</i> 2012; <b>122</b>(10): 3781–90. <a target=xrefwindow id=d70223e1403 href="http://www.ncbi.nlm.nih.gov/pubmed/22996451">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1406 href="http://dx.doi.org/10.1172/JCI64413">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1410 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3461925">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717970487">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1116217"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e1423 class=n-a></a>Ishii K, Lin C, Siegel DL, <i> et al.</i>: Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies. <i>J Invest Dermatol.</i> 2008; <b>128</b>(4): 939–48. <a target=xrefwindow id=d70223e1434 href="http://www.ncbi.nlm.nih.gov/pubmed/18007588">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1437 href="http://dx.doi.org/10.1038/sj.jid.5701132">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1441 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2597791">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1116217">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d70223e1455 class=n-a></a>Yeh SW, Cavacini LA, Bhol KC, <i> et al.</i>: Pathogenic human monoclonal antibody against desmoglein 3. <i>Clin Immunol.</i> 2006; <b>120</b>(1): 68–75. <a target=xrefwindow id=d70223e1466 href="http://www.ncbi.nlm.nih.gov/pubmed/16635589">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1469 href="http://dx.doi.org/10.1016/j.clim.2006.03.006">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d70223e1478 class=n-a></a>Amagai M, Hashimoto T, Shimizu N, <i> et al.</i>: Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. <i>J Clin Invest.</i> 1994; <b>94</b>(1): 59–67. <a target=xrefwindow id=d70223e1489 href="http://www.ncbi.nlm.nih.gov/pubmed/8040292">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1492 href="http://dx.doi.org/10.1172/JCI117349">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1496 href="http://www.ncbi.nlm.nih.gov/pmc/articles/296282">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d70223e1505 class=n-a></a>Amagai M, Hashimoto T, Green KJ, <i> et al.</i>: Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. <i>J Invest Dermatol.</i> 1995; <b>104</b>(6): 895–901. <a target=xrefwindow id=d70223e1516 href="http://www.ncbi.nlm.nih.gov/pubmed/7539469">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1519 href="http://dx.doi.org/10.1111/1523-1747.ep12606168">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d70223e1528 class=n-a></a>Mascaró JM Jr, España A, Liu Z, <i> et al.</i>: Mechanisms of acantholysis in pemphigus vulgaris: role of IgG valence. <i>Clin Immunol Immunopathol.</i> 1997; <b>85</b>(1): 90–6. <a target=xrefwindow id=d70223e1539 href="http://www.ncbi.nlm.nih.gov/pubmed/9325074">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1542 href="http://dx.doi.org/10.1006/clin.1997.4408">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d70223e1551 class=n-a></a>Rock B, Labib RS, Diaz LA: Monovalent Fab' immunoglobulin fragments from endemic pemphigus foliaceus autoantibodies reproduce the human disease in neonatal Balb/c mice. <i>J Clin Invest.</i> 1990; <b>85</b>(1): 296–9. <a target=xrefwindow id=d70223e1559 href="http://www.ncbi.nlm.nih.gov/pubmed/2295702">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1562 href="http://dx.doi.org/10.1172/JCI114426">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1565 href="http://www.ncbi.nlm.nih.gov/pmc/articles/296418">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717970092"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e1574 class=n-a></a>Saito M, Stahley SN, Caughman CY, <i> et al.</i>: Signaling dependent and independent mechanisms in pemphigus vulgaris blister formation. <i>PLoS One.</i> 2012; <b>7</b>(12): e50696. <a target=xrefwindow id=d70223e1585 href="http://www.ncbi.nlm.nih.gov/pubmed/23226536">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1588 href="http://dx.doi.org/10.1371/journal.pone.0050696">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1592 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3513318">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717970092">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/6622958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e1606 class=n-a></a>Mao X, Nagler AR, Farber SA, <i> et al.</i>: Autoimmunity to desmocollin 3 in pemphigus vulgaris. <i>Am J Pathol.</i> 2010; <b>177</b>(6): 2724–30. <a target=xrefwindow id=d70223e1617 href="http://www.ncbi.nlm.nih.gov/pubmed/20952584">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1620 href="http://dx.doi.org/10.2353/ajpath.2010.100483">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1624 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2993297">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/6622958">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/11613957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e1637 class=n-a></a>Rafei D, Müller R, Ishii N, <i> et al.</i>: IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion. <i>Am J Pathol.</i> 2011; <b>178</b>(2): 718–23. <a target=xrefwindow id=d70223e1648 href="http://www.ncbi.nlm.nih.gov/pubmed/21281804">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1651 href="http://dx.doi.org/10.1016/j.ajpath.2010.10.016">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1655 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3069870">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/11613957">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d70223e1668 class=n-a></a>Nguyen VT, Ndoye A, Grando SA: Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine. <i>J Biol Chem.</i> 2000; <b>275</b>(38): 29466–76. <a target=xrefwindow id=d70223e1676 href="http://www.ncbi.nlm.nih.gov/pubmed/10899159">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1679 href="http://dx.doi.org/10.1074/jbc.M003174200">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d70223e1688 class=n-a></a>Nguyen VT, Ndoye A, Grando SA: Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity. <i>Am J Pathol.</i> 2000; <b>157</b>(4): 1377–91. <a target=xrefwindow id=d70223e1696 href="http://www.ncbi.nlm.nih.gov/pubmed/11021840">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1699 href="http://dx.doi.org/10.1016/S0002-9440(10)64651-2">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1702 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1850172">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d70223e1711 class=n-a></a>Chen Y, Chernyavsky A, Webber RJ, <i> et al.</i>: Critical Role of the Neonatal Fc Receptor (FcRn) in the Pathogenic Action of Antimitochondrial Autoantibodies Synergizing with Anti-desmoglein Autoantibodies in Pemphigus Vulgaris. <i>J Biol Chem.</i> 2015; <b>290</b>(39): 23826–37. <a target=xrefwindow id=d70223e1722 href="http://www.ncbi.nlm.nih.gov/pubmed/26260795">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1725 href="http://dx.doi.org/10.1074/jbc.M115.668061">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1729 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4583029">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1089364"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e1738 class=n-a></a>Joly P, Mouquet H, Roujeau JC, <i> et al.</i>: A single cycle of rituximab for the treatment of severe pemphigus. <i>N Engl J Med.</i> 2007; <b>357</b>(6): 545–52. <a target=xrefwindow id=d70223e1749 href="http://www.ncbi.nlm.nih.gov/pubmed/17687130">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1752 href="http://dx.doi.org/10.1056/NEJMoa067752">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1089364">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1047012"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e1766 class=n-a></a>Ahmed AR, Spigelman Z, Cavacini LA, <i> et al.</i>: Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. <i>N Engl J Med.</i> 2006; <b>355</b>(17): 1772–9. <a target=xrefwindow id=d70223e1777 href="http://www.ncbi.nlm.nih.gov/pubmed/17065638">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1780 href="http://dx.doi.org/10.1056/NEJMoa062930">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1047012">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725438864"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e1793 class=n-a></a>Wang HH, Liu CW, Li YC, <i> et al.</i>: Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. <i>Acta Derm Venereol.</i> 2015; <b>95</b>(8): 928–32. <a target=xrefwindow id=d70223e1804 href="http://www.ncbi.nlm.nih.gov/pubmed/25881672">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1807 href="http://dx.doi.org/10.2340/00015555-2116">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725438864">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717987555"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e1820 class=n-a></a>Colliou N, Picard D, Caillot F, <i> et al.</i>: Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. <i>Sci Transl Med.</i> 2013; <b>5</b>(175): 175ra30. <a target=xrefwindow id=d70223e1831 href="http://www.ncbi.nlm.nih.gov/pubmed/23467561">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1834 href="http://dx.doi.org/10.1126/scitranslmed.3005166">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717987555">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d70223e1847 class=n-a></a>Ahmed AR, Kaveri S, Spigelman Z: Long-Term Remissions in Recalcitrant Pemphigus Vulgaris. <i>N Engl J Med.</i> 2015; <b>373</b>(27): 2693–4. <a target=xrefwindow id=d70223e1855 href="http://www.ncbi.nlm.nih.gov/pubmed/26716930">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1858 href="http://dx.doi.org/10.1056/NEJMc1508234">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d70223e1867 class=n-a></a>Hammers CM, Chen J, Lin C, <i> et al.</i>: Persistence of anti-desmoglein 3 IgG<sup>+</sup> B-cell clones in pemphigus patients over years. <i>J Invest Dermatol.</i> 2015; <b>135</b>(3): 742–9. <a target=xrefwindow id=d70223e1881 href="http://www.ncbi.nlm.nih.gov/pubmed/25142730">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1885 href="http://dx.doi.org/10.1038/jid.2014.291">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1888 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4294994">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717948523"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e1897 class=n-a></a>Lunardon L, Tsai KJ, Propert KJ, <i> et al.</i>: Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. <i>Arch Dermatol.</i> 2012; <b>148</b>(9): 1031–6. <a target=xrefwindow id=d70223e1908 href="http://www.ncbi.nlm.nih.gov/pubmed/22710375">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1911 href="http://dx.doi.org/10.1001/archdermatol.2012.1522">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1915 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3658473">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717948523">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1028244"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e1929 class=n-a></a>Lennon VA, Kryzer TJ, Pittock SJ, <i> et al.</i>: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. <i>J Exp Med.</i> 2005; <b>202</b>(4): 473–7. <a target=xrefwindow id=d70223e1940 href="http://www.ncbi.nlm.nih.gov/pubmed/16087714">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1943 href="http://dx.doi.org/10.1084/jem.20050304">Publisher Full Text </a> | <a target=xrefwindow id=d70223e1947 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2212860">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1028244">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d70223e1960 class=n-a></a>Lennon VA, Wingerchuk DM, Kryzer TJ, <i> et al.</i>: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. <i>Lancet.</i> 2004; <b>364</b>(9451): 2106–12. <a target=xrefwindow id=d70223e1971 href="http://www.ncbi.nlm.nih.gov/pubmed/15589308">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1974 href="http://dx.doi.org/10.1016/S0140-6736(04)17551-X">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1086961"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e1983 class=n-a></a>Roemer SF, Parisi JE, Lennon VA, <i> et al.</i>: Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. <i>Brain.</i> 2007; <b>130</b>(Pt 5): 1194–205. <a target=xrefwindow id=d70223e1994 href="http://www.ncbi.nlm.nih.gov/pubmed/17282996">PubMed Abstract </a> | <a target=xrefwindow id=d70223e1997 href="http://dx.doi.org/10.1093/brain/awl371">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1086961">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725572558"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e2010 class=n-a></a>Wingerchuk DM, Banwell B, Bennett JL, <i> et al.</i>: International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology.</i> 2015; <b>85</b>(2): 177–89. <a target=xrefwindow id=d70223e2021 href="http://www.ncbi.nlm.nih.gov/pubmed/26092914">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2024 href="http://dx.doi.org/10.1212/WNL.0000000000001729">Publisher Full Text </a> | <a target=xrefwindow id=d70223e2028 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4515040">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725572558">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d70223e2041 class=n-a></a>Waters PJ, McKeon A, Leite MI, <i> et al.</i>: Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. <i>Neurology.</i> 2012; <b>78</b>(9): 665–71; discussion 669. <a target=xrefwindow id=d70223e2052 href="http://www.ncbi.nlm.nih.gov/pubmed/22302543">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2055 href="http://dx.doi.org/10.1212/WNL.0b013e318248dec1">Publisher Full Text </a> | <a target=xrefwindow id=d70223e2059 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3286228">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d70223e2068 class=n-a></a>Jiao Y, Fryer JP, Lennon VA, <i> et al.</i>: Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. <i>Neurology.</i> 2013; <b>81</b>(14): 1197–204. <a target=xrefwindow id=d70223e2079 href="http://www.ncbi.nlm.nih.gov/pubmed/23997151">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2082 href="http://dx.doi.org/10.1212/WNL.0b013e3182a6cb5c">Publisher Full Text </a> | <a target=xrefwindow id=d70223e2086 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3795610">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d70223e2096 class=n-a></a>Isobe N, Yonekawa T, Matsushita T, <i> et al.</i>: Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica. <i>Mult Scler.</i> 2012; <b>18</b>(11): 1541–51. <a target=xrefwindow id=d70223e2107 href="http://www.ncbi.nlm.nih.gov/pubmed/22526930">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2110 href="http://dx.doi.org/10.1177/1352458512443917">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d70223e2119 class=n-a></a>Isobe N, Yonekawa T, Matsushita T, <i> et al.</i>: Clinical relevance of serum aquaporin-4 antibody levels in neuromyelitis optica. <i>Neurochem Res.</i> 2013; <b>38</b>(5): 997–1001. <a target=xrefwindow id=d70223e2130 href="http://www.ncbi.nlm.nih.gov/pubmed/23456674">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2133 href="http://dx.doi.org/10.1007/s11064-013-1009-0">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d70223e2142 class=n-a></a>Weinshenker BG, Wingerchuk DM, Vukusic S, <i> et al.</i>: Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. <i>Ann Neurol.</i> 2006; <b>59</b>(3): 566–9. <a target=xrefwindow id=d70223e2153 href="http://www.ncbi.nlm.nih.gov/pubmed/16453327">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2156 href="http://dx.doi.org/10.1002/ana.20770">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d70223e2165 class=n-a></a>Takahashi T, Fujihara K, Nakashima I, <i> et al.</i>: Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. <i>Brain.</i> 2007; <b>130</b>(Pt 5): 1235–43. <a target=xrefwindow id=d70223e2176 href="http://www.ncbi.nlm.nih.gov/pubmed/17449477">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2179 href="http://dx.doi.org/10.1093/brain/awm062">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d70223e2188 class=n-a></a>Jarius S, Aboul-Enein F, Waters P, <i> et al.</i>: Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. <i>Brain.</i> 2008; <b>131</b>(Pt 11): 3072–80. <a target=xrefwindow id=d70223e2199 href="http://www.ncbi.nlm.nih.gov/pubmed/18945724">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2202 href="http://dx.doi.org/10.1093/brain/awn240">Publisher Full Text </a> | <a target=xrefwindow id=d70223e2206 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2577801">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d70223e2215 class=n-a></a>Saini H, Rifkin R, Gorelik M, <i> et al.</i>: Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis. <i>BMC Neurol.</i> 2013; <b>13</b>: 104. <a target=xrefwindow id=d70223e2226 href="http://www.ncbi.nlm.nih.gov/pubmed/23927715">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2229 href="http://dx.doi.org/10.1186/1471-2377-13-104">Publisher Full Text </a> | <a target=xrefwindow id=d70223e2233 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3750922">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d70223e2243 class=n-a></a>Bennett JL, Lam C, Kalluri SR, <i> et al.</i>: Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. <i>Ann Neurol.</i> 2009; <b>66</b>(5): 617–29. <a target=xrefwindow id=d70223e2254 href="http://www.ncbi.nlm.nih.gov/pubmed/19938104">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2257 href="http://dx.doi.org/10.1002/ana.21802">Publisher Full Text </a> | <a target=xrefwindow id=d70223e2261 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3180961">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d70223e2270 class=n-a></a>Bradl M, Misu T, Takahashi T, <i> et al.</i>: Neuromyelitis optica: pathogenicity of patient immunoglobulin <i>in vivo</i>. <i>Ann Neurol.</i> 2009; <b>66</b>(5): 630–43. <a target=xrefwindow id=d70223e2284 href="http://www.ncbi.nlm.nih.gov/pubmed/19937948">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2288 href="http://dx.doi.org/10.1002/ana.21837">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d70223e2297 class=n-a></a>Kinoshita M, Nakatsuji Y, Kimura T, <i> et al.</i>: Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. <i>Biochem Biophys Res Commun.</i> 2009; <b>386</b>(4): 623–7. <a target=xrefwindow id=d70223e2308 href="http://www.ncbi.nlm.nih.gov/pubmed/19545538">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2311 href="http://dx.doi.org/10.1016/j.bbrc.2009.06.085">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725454279"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e2320 class=n-a></a>Abboud H, Petrak A, Mealy M, <i> et al.</i>: Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. <i>Mult Scler.</i> 2016; <b>22</b>(2): 185–92. <a target=xrefwindow id=d70223e2331 href="http://www.ncbi.nlm.nih.gov/pubmed/25921047">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2334 href="http://dx.doi.org/10.1177/1352458515581438">Publisher Full Text </a> | <a target=xrefwindow id=d70223e2338 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4795457">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725454279">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d70223e2351 class=n-a></a>Watanabe S, Nakashima I, Misu T, <i> et al.</i>: Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. <i>Mult Scler.</i> 2007; <b>13</b>(1): 128–32. <a target=xrefwindow id=d70223e2362 href="http://www.ncbi.nlm.nih.gov/pubmed/17294622">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2365 href="http://dx.doi.org/10.1177/1352458506071174">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d70223e2374 class=n-a></a>Bonnan M, Valentino R, Olindo S, <i> et al.</i>: Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. <i>Mult Scler.</i> 2009; <b>15</b>(4): 487–92. <a target=xrefwindow id=d70223e2385 href="http://www.ncbi.nlm.nih.gov/pubmed/19324982">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2388 href="http://dx.doi.org/10.1177/1352458508100837">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725915202"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e2398 class=n-a></a>Kleiter I, Gahlen A, Borisow N, <i> et al.</i>: Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Ann Neurol.</i> 2016; <b>79</b>(2): 206–16. <a target=xrefwindow id=d70223e2409 href="http://www.ncbi.nlm.nih.gov/pubmed/26537743">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2412 href="http://dx.doi.org/10.1002/ana.24554">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725915202">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725506435"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e2425 class=n-a></a>Jones MV, Huang H, Calabresi PA, <i> et al.</i>: Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica. <i>Acta Neuropathol Commun.</i> 2015; <b>3</b>: 28. <a target=xrefwindow id=d70223e2436 href="http://www.ncbi.nlm.nih.gov/pubmed/25990016">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2439 href="http://dx.doi.org/10.1186/s40478-015-0207-1">Publisher Full Text </a> | <a target=xrefwindow id=d70223e2443 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4438510">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725506435">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d70223e2456 class=n-a></a>Cree BA, Lamb S, Morgan K, <i> et al.</i>: An open label study of the effects of rituximab in neuromyelitis optica. <i>Neurology.</i> 2005; <b>64</b>(7): 1270–2. <a target=xrefwindow id=d70223e2467 href="http://www.ncbi.nlm.nih.gov/pubmed/15824362">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2470 href="http://dx.doi.org/10.1212/01.WNL.0000159399.81861.D5">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725783000"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e2479 class=n-a></a>Collongues N, Brassat D, Maillart E, <i> et al.</i>: Efficacy of rituximab in refractory neuromyelitis optica. <i>Mult Scler.</i> 2016; <b>22</b>(7): 955–9. <a target=xrefwindow id=d70223e2490 href="http://www.ncbi.nlm.nih.gov/pubmed/26362900">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2493 href="http://dx.doi.org/10.1177/1352458515602337">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725783000">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725664459"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e2506 class=n-a></a>Zéphir H, Bernard-Valnet R, Lebrun C, <i> et al.</i>: Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. <i>J Neurol.</i> 2015; <b>262</b>(10): 2329–35. <a target=xrefwindow id=d70223e2517 href="http://www.ncbi.nlm.nih.gov/pubmed/26194198">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2520 href="http://dx.doi.org/10.1007/s00415-015-7852-y">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725664459">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727195785"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e2533 class=n-a></a>Mealy MA, Wingerchuk DM, Palace J, <i> et al.</i>: Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. <i>JAMA Neurol.</i> 2014; <b>71</b>(3): 324–30. <a target=xrefwindow id=d70223e2544 href="http://www.ncbi.nlm.nih.gov/pubmed/24445513">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2547 href="http://dx.doi.org/10.1001/jamaneurol.2013.5699">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727195785">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725649162"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e2561 class=n-a></a>Kim S, Jeong IH, Hyun Jw, <i> et al.</i>: Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of <i>FCGR3A</i> Polymorphisms on the Therapeutic Response to Rituximab. <i>JAMA Neurol.</i> 2015; <b>72</b>(9): 989–95. <a target=xrefwindow id=d70223e2575 href="http://www.ncbi.nlm.nih.gov/pubmed/26167726">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2579 href="http://dx.doi.org/10.1001/jamaneurol.2015.1276">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725649162">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725664178"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e2592 class=n-a></a>Radaelli M, Moiola L, Sangalli F, <i> et al.</i>: Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. <i>Mult Scler.</i> 2016; <b>22</b>(4): 511–9. <a target=xrefwindow id=d70223e2603 href="http://www.ncbi.nlm.nih.gov/pubmed/26199350">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2606 href="http://dx.doi.org/10.1177/1352458515594042">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725664178">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d70223e2619 class=n-a></a>Sellner J, Boggild M, Clanet M, <i> et al.</i>: EFNS guidelines on diagnosis and management of neuromyelitis optica. <i>Eur J Neurol.</i> 2010; <b>17</b>(8): 1019–32. <a target=xrefwindow id=d70223e2630 href="http://www.ncbi.nlm.nih.gov/pubmed/20528913">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2633 href="http://dx.doi.org/10.1111/j.1468-1331.2010.03066.x">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d70223e2642 class=n-a></a>Soejima K, Matsumoto M, Kokame K, <i> et al.</i>: ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. <i>Blood.</i> 2003; <b>102</b>(9): 3232–7. <a target=xrefwindow id=d70223e2653 href="http://www.ncbi.nlm.nih.gov/pubmed/12869506">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2656 href="http://dx.doi.org/10.1182/blood-2003-03-0908">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d70223e2665 class=n-a></a>Tsai HM, Lian EC: Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. <i>N Engl J Med.</i> 1998; <b>339</b>(22): 1585–94. <a target=xrefwindow id=d70223e2673 href="http://www.ncbi.nlm.nih.gov/pubmed/9828246">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2676 href="http://dx.doi.org/10.1056/NEJM199811263392203">Publisher Full Text </a> | <a target=xrefwindow id=d70223e2679 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3159001">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d70223e2688 class=n-a></a>Scheiflinger F, Knöbl P, Trattner B, <i> et al.</i>: Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. <i>Blood.</i> 2003; <b>102</b>(9): 3241–3. <a target=xrefwindow id=d70223e2699 href="http://www.ncbi.nlm.nih.gov/pubmed/12855569">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2702 href="http://dx.doi.org/10.1182/blood-2003-05-1616">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d70223e2712 class=n-a></a>Rieger M, Mannucci PM, Kremer Hovinga JA, <i> et al.</i>: ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. <i>Blood.</i> 2005; <b>106</b>(4): 1262–7. <a target=xrefwindow id=d70223e2723 href="http://www.ncbi.nlm.nih.gov/pubmed/15890682">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2726 href="http://dx.doi.org/10.1182/blood-2004-11-4490">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d70223e2735 class=n-a></a>Scully M, Yarranton H, Liesner R, <i> et al.</i>: Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. <i>Br J Haematol.</i> 2008; <b>142</b>(5): 819–26. <a target=xrefwindow id=d70223e2746 href="http://www.ncbi.nlm.nih.gov/pubmed/18637802">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2749 href="http://dx.doi.org/10.1111/j.1365-2141.2008.07276.x">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d70223e2758 class=n-a></a>Grillberger R, Casina VC, Turecek PL, <i> et al.</i>: Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura. <i>Haematologica.</i> 2014; <b>99</b>(4): e58–60. <a target=xrefwindow id=d70223e2769 href="http://www.ncbi.nlm.nih.gov/pubmed/24532042">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2772 href="http://dx.doi.org/10.3324/haematol.2013.100685">Publisher Full Text </a> | <a target=xrefwindow id=d70223e2776 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3971096">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d70223e2785 class=n-a></a>Zheng XL, Kaufman RM, Goodnough LT, <i> et al.</i>: Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. <i>Blood.</i> 2004; <b>103</b>(11): 4043–9. <a target=xrefwindow id=d70223e2796 href="http://www.ncbi.nlm.nih.gov/pubmed/14982878">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2799 href="http://dx.doi.org/10.1182/blood-2003-11-4035">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d70223e2808 class=n-a></a>Böhm M, Betz C, Miesbach W, <i> et al.</i>: The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. <i>Br J Haematol.</i> 2005; <b>129</b>(5): 644–52. <a target=xrefwindow id=d70223e2819 href="http://www.ncbi.nlm.nih.gov/pubmed/15916687">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2822 href="http://dx.doi.org/10.1111/j.1365-2141.2005.05512.x">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d70223e2831 class=n-a></a>Vesely SK, George JN, Lämmle B, <i> et al.</i>: ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. <i>Blood.</i> 2003; <b>102</b>(1): 60–8. <a target=xrefwindow id=d70223e2842 href="http://www.ncbi.nlm.nih.gov/pubmed/12637323">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2845 href="http://dx.doi.org/10.1182/blood-2003-01-0193">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d70223e2855 class=n-a></a>Feys HB, Roodt J, Vandeputte N, <i> et al.</i>: Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (<i>Papio ursinus</i>). <i>Blood.</i> 2010; <b>116</b>(12): 2005–10. <a target=xrefwindow id=d70223e2869 href="http://www.ncbi.nlm.nih.gov/pubmed/20551375">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2873 href="http://dx.doi.org/10.1182/blood-2010-04-280479">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726264102"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e2882 class=n-a></a>Ostertag EM, Bdeir K, Kacir S, <i> et al.</i>: ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model. <i>Transfusion.</i> 2016; <b>56</b>(7): 1775–85. <a target=xrefwindow id=d70223e2893 href="http://www.ncbi.nlm.nih.gov/pubmed/27040023">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2896 href="http://dx.doi.org/10.1111/trf.13583">Publisher Full Text </a> | <a target=xrefwindow id=d70223e2900 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4938757">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726264102">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d70223e2913 class=n-a></a>Bell WR, Braine HG, Ness PM, <i> et al.</i>: Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. <i>N Engl J Med.</i> 1991; <b>325</b>(6): 398–403. <a target=xrefwindow id=d70223e2924 href="http://www.ncbi.nlm.nih.gov/pubmed/2062331">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2927 href="http://dx.doi.org/10.1056/NEJM199108083250605">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d70223e2936 class=n-a></a>Rock GA, Shumak KH, Buskard NA, <i> et al.</i>: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. <i>N Engl J Med.</i> 1991; <b>325</b>(6): 393–7. <a target=xrefwindow id=d70223e2947 href="http://www.ncbi.nlm.nih.gov/pubmed/2062330">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2950 href="http://dx.doi.org/10.1056/NEJM199108083250604">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d70223e2959 class=n-a></a>von Baeyer H: Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. <i>Ther Apher.</i> 2002; <b>6</b>(4): 320–8. <a target=xrefwindow id=d70223e2967 href="http://www.ncbi.nlm.nih.gov/pubmed/12164804">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2970 href="http://dx.doi.org/10.1046/j.1526-0968.2002.00390.x">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d70223e2979 class=n-a></a>Lim W, Vesely SK, George JN: The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. <i>Blood.</i> 2015; <b>125</b>(10): 1526–31. <a target=xrefwindow id=d70223e2987 href="http://www.ncbi.nlm.nih.gov/pubmed/25573992">PubMed Abstract </a> | <a target=xrefwindow id=d70223e2990 href="http://dx.doi.org/10.1182/blood-2014-10-559211">Publisher Full Text </a> | <a target=xrefwindow id=d70223e2993 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4351502">Free Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d70223e3003 class=n-a></a>Froissart A, Buffet M, Veyradier A, <i> et al.</i>: Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. <i>Crit Care Med.</i> 2012; <b>40</b>(1): 104–11. <a target=xrefwindow id=d70223e3014 href="http://www.ncbi.nlm.nih.gov/pubmed/21926591">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3017 href="http://dx.doi.org/10.1097/CCM.0b013e31822e9d66">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d70223e3026 class=n-a></a>Scully M, McDonald V, Cavenagh J, <i> et al.</i>: A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. <i>Blood.</i> 2011; <b>118</b>(7): 1746–53. <a target=xrefwindow id=d70223e3037 href="http://www.ncbi.nlm.nih.gov/pubmed/21636861">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3040 href="http://dx.doi.org/10.1182/blood-2011-03-341131">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d70223e3049 class=n-a></a>Scully M, Hunt BJ, Benjamin S, <i> et al.</i>: Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. <i>Br J Haematol.</i> 2012; <b>158</b>(3): 323–35. <a target=xrefwindow id=d70223e3060 href="http://www.ncbi.nlm.nih.gov/pubmed/22624596">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3063 href="http://dx.doi.org/10.1111/j.1365-2141.2012.09167.x">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d70223e3072 class=n-a></a>Simpson JA: ‘Myasthenia Gravis: A New Hypothesis’. <i>Scott Med J.</i> 1960; <b>5</b>(10): 419–436. <a target=xrefwindow id=d70223e3080 href="http://dx.doi.org/10.1177/003693306000501001">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d70223e3089 class=n-a></a>Lennon VA, Seybold ME, Lindstrom JM, <i> et al.</i>: Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. <i>J Exp Med.</i> 1978; <b>147</b>(4): 973–83. <a target=xrefwindow id=d70223e3100 href="http://www.ncbi.nlm.nih.gov/pubmed/206648">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3103 href="http://dx.doi.org/10.1084/jem.147.4.973">Publisher Full Text </a> | <a target=xrefwindow id=d70223e3107 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2184243">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d70223e3116 class=n-a></a>Biesecker G, Gomez CM: Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. <i>J Immunol.</i> 1989; <b>142</b>(8): 2654–9. <a target=xrefwindow id=d70223e3124 href="http://www.ncbi.nlm.nih.gov/pubmed/2703710">PubMed Abstract </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d70223e3134 class=n-a></a>Piddlesden SJ, Jiang S, Levin JL, <i> et al.</i>: Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. <i>J Neuroimmunol.</i> 1996; <b>71</b>(1–2): 173–7. <a target=xrefwindow id=d70223e3145 href="http://www.ncbi.nlm.nih.gov/pubmed/8982117">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3148 href="http://dx.doi.org/10.1016/S0165-5728(96)00144-0%0A">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d70223e3157 class=n-a></a>Lin F, Kaminski HJ, Conti-Fine BM, <i> et al.</i>: Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. <i>J Clin Invest.</i> 2002; <b>110</b>(9): 1269–74. <a target=xrefwindow id=d70223e3168 href="http://www.ncbi.nlm.nih.gov/pubmed/12417565">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3171 href="http://dx.doi.org/10.1172/JCI16086">Publisher Full Text </a> | <a target=xrefwindow id=d70223e3175 href="http://www.ncbi.nlm.nih.gov/pmc/articles/151616">Free Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d70223e3184 class=n-a></a>Drachman DB, Angus CW, Adams RN, <i> et al.</i>: Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. <i>N Engl J Med.</i> 1978; <b>298</b>(20): 1116–22. <a target=xrefwindow id=d70223e3195 href="http://www.ncbi.nlm.nih.gov/pubmed/643030">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3198 href="http://dx.doi.org/10.1056/NEJM197805182982004">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d70223e3207 class=n-a></a>Gomez CM, Richman DP: Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. <i>Proc Natl Acad Sci U S A.</i> 1983; <b>80</b>(13): 4089–93. <a target=xrefwindow id=d70223e3215 href="http://www.ncbi.nlm.nih.gov/pubmed/6575398">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3218 href="http://dx.doi.org/10.1073/pnas.80.13.4089">Publisher Full Text </a> | <a target=xrefwindow id=d70223e3221 href="http://www.ncbi.nlm.nih.gov/pmc/articles/394206">Free Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d70223e3230 class=n-a></a>Sanders DB, Burns TM, Cutter GR, <i> et al.</i>: Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? <i>Muscle Nerve.</i> 2014; <b>49</b>(4): 483–6. <a target=xrefwindow id=d70223e3241 href="http://www.ncbi.nlm.nih.gov/pubmed/23835683">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3244 href="http://dx.doi.org/10.1002/mus.23944">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d70223e3253 class=n-a></a>Toyka KV, Brachman DB, Pestronk A, <i> et al.</i>: Myasthenia gravis: passive transfer from man to mouse. <i>Science.</i> 1975; <b>190</b>(4212): 397–9. <a target=xrefwindow id=d70223e3264 href="http://www.ncbi.nlm.nih.gov/pubmed/1179220">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3267 href="http://dx.doi.org/10.1126/science.1179220">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d70223e3277 class=n-a></a>Hoch W, McConville J, Helms S, <i> et al.</i>: Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. <i>Nat Med.</i> 2001; <b>7</b>(3): 365–8. <a target=xrefwindow id=d70223e3288 href="http://www.ncbi.nlm.nih.gov/pubmed/11231638">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3291 href="http://dx.doi.org/10.1038/85520">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d70223e3300 class=n-a></a>McConville J, Farrugia ME, Beeson D, <i> et al.</i>: Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. <i>Ann Neurol.</i> 2004; <b>55</b>(4): 580–4. <a target=xrefwindow id=d70223e3311 href="http://www.ncbi.nlm.nih.gov/pubmed/15048899">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3314 href="http://dx.doi.org/10.1002/ana.20061">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d70223e3323 class=n-a></a>Yeh JH, Chen WH, Chiu HC, <i> et al.</i>: Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. <i>Neurology.</i> 2004; <b>62</b>(11): 2131–2. <a target=xrefwindow id=d70223e3334 href="http://www.ncbi.nlm.nih.gov/pubmed/15184635">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3337 href="http://dx.doi.org/10.1212/01.WNL.0000128042.28877.C3">Publisher Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d70223e3346 class=n-a></a>Vincent A, Bowen J, Newsom-Davis J, <i> et al.</i>: Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. <i>Lancet Neurol.</i> 2003; <b>2</b>(2): 99–106. <a target=xrefwindow id=d70223e3357 href="http://www.ncbi.nlm.nih.gov/pubmed/12849266">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3360 href="http://dx.doi.org/10.1016/S1474-4422(03)00306-5">Publisher Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d70223e3369 class=n-a></a>Shiraishi H, Motomura M, Yoshimura T, <i> et al.</i>: Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. <i>Ann Neurol.</i> 2005; <b>57</b>(2): 289–93. <a target=xrefwindow id=d70223e3380 href="http://www.ncbi.nlm.nih.gov/pubmed/15668981">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3383 href="http://dx.doi.org/10.1002/ana.20341">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d70223e3392 class=n-a></a>Selcen D, Fukuda T, Shen XM, <i> et al.</i>: Are MuSK antibodies the primary cause of myasthenic symptoms? <i>Neurology.</i> 2004; <b>62</b>(11): 1945–50. <a target=xrefwindow id=d70223e3403 href="http://www.ncbi.nlm.nih.gov/pubmed/15184594">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3406 href="http://dx.doi.org/10.1212/01.WNL.0000128048.23930.1D">Publisher Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d70223e3416 class=n-a></a>Cole RN, Reddel SW, Gervásio OL, <i> et al.</i>: Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. <i>Ann Neurol.</i> 2008; <b>63</b>(6): 782–9. <a target=xrefwindow id=d70223e3427 href="http://www.ncbi.nlm.nih.gov/pubmed/18384168">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3430 href="http://dx.doi.org/10.1002/ana.21371">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d70223e3439 class=n-a></a>Guptill JT, Sanders DB, Evoli A: Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. <i>Muscle Nerve.</i> 2011; <b>44</b>(1): 36–40. <a target=xrefwindow id=d70223e3447 href="http://www.ncbi.nlm.nih.gov/pubmed/21674519">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3450 href="http://dx.doi.org/10.1002/mus.22006">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718317674"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e3459 class=n-a></a>Sun F, Ladha SS, Yang L, <i> et al.</i>: Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis. <i>Muscle Nerve.</i> 2014; <b>49</b>(4): 487–94. <a target=xrefwindow id=d70223e3470 href="http://www.ncbi.nlm.nih.gov/pubmed/23868194">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3473 href="http://dx.doi.org/10.1002/mus.23951">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718317674">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d70223e3486 class=n-a></a>Díaz-Manera J, Martínez-Hernández E, Querol L, <i> et al.</i>: Long-lasting treatment effect of rituximab in MuSK myasthenia. <i>Neurology.</i> 2012; <b>78</b>(3): 189–93. <a target=xrefwindow id=d70223e3497 href="http://www.ncbi.nlm.nih.gov/pubmed/22218276">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3500 href="http://dx.doi.org/10.1212/WNL.0b013e3182407982">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/721807471"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e3509 class=n-a></a>Iorio R, Damato V, Alboini PE, <i> et al.</i>: Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. <i>J Neurol.</i> 2015; <b>262</b>(5): 1115–9. <a target=xrefwindow id=d70223e3520 href="http://www.ncbi.nlm.nih.gov/pubmed/25308632">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3523 href="http://dx.doi.org/10.1007/s00415-014-7532-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/721807471">F1000 Recommendation</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d70223e3536 class=n-a></a>Kamijo K, Murayama H, Uzu T, <i> et al.</i>: A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells. <i>Thyroid.</i> 2010; <b>20</b>(8): 851–6. <a target=xrefwindow id=d70223e3547 href="http://www.ncbi.nlm.nih.gov/pubmed/20615137">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3550 href="http://dx.doi.org/10.1089/thy.2010.0059">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d70223e3560 class=n-a></a>Michelangeli V, Poon C, Taft J, <i> et al.</i>: The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. <i>Thyroid.</i> 1998; <b>8</b>(2): 119–24. <a target=xrefwindow id=d70223e3571 href="http://www.ncbi.nlm.nih.gov/pubmed/9510119">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3574 href="http://dx.doi.org/10.1089/thy.1998.8.119">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d70223e3583 class=n-a></a>Adams DD, Fastier FN, Howie JB, <i> et al.</i>: Stimulation of the human thyroid by infusions of plasma containing LATS protector. <i>J Clin Endocrinol Metab.</i> 1974; <b>39</b>(5): 826–32. <a target=xrefwindow id=d70223e3594 href="http://www.ncbi.nlm.nih.gov/pubmed/4425101">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3597 href="http://dx.doi.org/10.1210/jcem-39-5-826">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d70223e3606 class=n-a></a>McKenzie JM, Zakarija M: Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. <i>Thyroid.</i> 1992; <b>2</b>(2): 155–9. <a target=xrefwindow id=d70223e3614 href="http://www.ncbi.nlm.nih.gov/pubmed/1356056">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3617 href="http://dx.doi.org/10.1089/thy.1992.2.155">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d70223e3626 class=n-a></a>Evans M, Sanders J, Tagami T, <i> et al.</i>: Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample. <i>Clin Endocrinol (Oxf).</i> 2010; <b>73</b>(3): 404–12. <a target=xrefwindow id=d70223e3637 href="http://www.ncbi.nlm.nih.gov/pubmed/20550534">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3640 href="http://dx.doi.org/10.1111/j.1365-2265.2010.03831.x">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d70223e3649 class=n-a></a>Sanders J, Evans M, Premawardhana LD, <i> et al.</i>: Human monoclonal thyroid stimulating autoantibody. <i>Lancet.</i> 2003; <b>362</b>(9378): 126–8. <a target=xrefwindow id=d70223e3660 href="http://www.ncbi.nlm.nih.gov/pubmed/12867115">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3663 href="http://dx.doi.org/10.1016/S0140-6736(03)13866-4">Publisher Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d70223e3672 class=n-a></a>Sanders J, Jeffreys J, Depraetere H, <i> et al.</i>: Characteristics of a human monoclonal autoantibody to the thyrotropin receptor: sequence structure and function. <i>Thyroid.</i> 2004; <b>14</b>(8): 560–70. <a target=xrefwindow id=d70223e3683 href="http://www.ncbi.nlm.nih.gov/pubmed/15320966">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3686 href="http://dx.doi.org/10.1089/1050725041692918">Publisher Full Text </a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d70223e3696 class=n-a></a>Salvi M, Vannucchi G, Beck-Peccoz P: Potential utility of rituximab for Graves' orbitopathy. <i>J Clin Endocrinol Metab.</i> 2013; <b>98</b>(11): 4291–9. <a target=xrefwindow id=d70223e3704 href="http://www.ncbi.nlm.nih.gov/pubmed/24009135">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3707 href="http://dx.doi.org/10.1210/jc.2013-1804">Publisher Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/723891046"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e3716 class=n-a></a>Stan MN, Garrity JA, Carranza Leon BG, <i> et al.</i>: Randomized controlled trial of rituximab in patients with Graves' orbitopathy. <i>J Clin Endocrinol Metab.</i> 2015; <b>100</b>(2): 432–41. <a target=xrefwindow id=d70223e3727 href="http://www.ncbi.nlm.nih.gov/pubmed/25343233">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3730 href="http://dx.doi.org/10.1210/jc.2014-2572">Publisher Full Text </a> | <a target=xrefwindow id=d70223e3734 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4318907">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/723891046">F1000 Recommendation</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725276554"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e3747 class=n-a></a>Salvi M, Vannucchi G, Currò N, <i> et al.</i>: Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. <i>J Clin Endocrinol Metab.</i> 2015; <b>100</b>(2): 422–31. <a target=xrefwindow id=d70223e3758 href="http://www.ncbi.nlm.nih.gov/pubmed/25494967">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3761 href="http://dx.doi.org/10.1210/jc.2014-3014">Publisher Full Text </a> | <a target=xrefwindow id=d70223e3765 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4318899">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725276554">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d70223e3778 class=n-a></a>Bartalena L, Baldeschi L, Boboridis K, <i> et al.</i>: The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. <i>Eur Thyroid J.</i> 2016; <b>5</b>(1): 9–26. <a target=xrefwindow id=d70223e3789 href="http://www.ncbi.nlm.nih.gov/pubmed/27099835">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3792 href="http://dx.doi.org/10.1159/000443828">Publisher Full Text </a> | <a target=xrefwindow id=d70223e3796 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4836120">Free Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d70223e3805 class=n-a></a>Shulman NR, Marder VJ, Weinrach RS: Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. <i>Ann N Y Acad Sci.</i> 1965; <b>124</b>(2): 499–542. <a target=xrefwindow id=d70223e3813 href="http://www.ncbi.nlm.nih.gov/pubmed/5214832">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3816 href="http://dx.doi.org/10.1111/j.1749-6632.1965.tb18984.x">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d70223e3825 class=n-a></a>van Leeuwen EF, van der Ven JT, Engelfriet CP, <i> et al.</i>: Specificity of autoantibodies in autoimmune thrombocytopenia. <i>Blood.</i> 1982; <b>59</b>(1): 23–6. <a target=xrefwindow id=d70223e3836 href="http://www.ncbi.nlm.nih.gov/pubmed/7032627">PubMed Abstract </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d70223e3846 class=n-a></a>McMillan R, Wang L, Tani P: Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). <i>J Thromb Haemost.</i> 2003; <b>1</b>(3): 485–91. <a target=xrefwindow id=d70223e3854 href="http://www.ncbi.nlm.nih.gov/pubmed/12871454">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3857 href="http://dx.doi.org/10.1046/j.1538-7836.2003.00091.x">Publisher Full Text </a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d70223e3866 class=n-a></a>Warner MN, Moore JC, Warkentin TE, <i> et al.</i>: A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. <i>Br J Haematol.</i> 1999; <b>104</b>(3): 442–7. <a target=xrefwindow id=d70223e3877 href="http://www.ncbi.nlm.nih.gov/pubmed/10086776">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3880 href="http://dx.doi.org/10.1046/j.1365-2141.1999.01218.x">Publisher Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d70223e3889 class=n-a></a>Brighton TA, Evans S, Castaldi PA, <i> et al.</i>: Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. <i>Blood.</i> 1996; <b>88</b>(1): 194–201. <a target=xrefwindow id=d70223e3900 href="http://www.ncbi.nlm.nih.gov/pubmed/8704174">PubMed Abstract </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d70223e3909 class=n-a></a>Tsubakio T, Tani P, Curd JG, <i> et al.</i>: Complement activation <i>in vitro</i> by antiplatelet antibodies in chronic immune thrombocytopenic purpura. <i>Br J Haematol.</i> 1986; <b>63</b>(2): 293–300. <a target=xrefwindow id=d70223e3923 href="http://www.ncbi.nlm.nih.gov/pubmed/3718872">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3927 href="http://dx.doi.org/10.1111/j.1365-2141.1986.tb05552.x">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d70223e3936 class=n-a></a>Takahashi R, Sekine N, Nakatake T: Influence of monoclonal antiplatelet glycoprotein antibodies on <i>in vitro</i> human megakaryocyte colony formation and proplatelet formation. <i>Blood.</i> 1999; <b>93</b>(6): 1951–8. <a target=xrefwindow id=d70223e3947 href="http://www.ncbi.nlm.nih.gov/pubmed/10068668">PubMed Abstract </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d70223e3956 class=n-a></a>Harrington WJ, Sprague CC, Minnich V, <i> et al.</i>: Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. <i>Ann Intern Med.</i> 1953; <b>38</b>(3): 433–69. <a target=xrefwindow id=d70223e3967 href="http://www.ncbi.nlm.nih.gov/pubmed/13031392">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3970 href="http://dx.doi.org/10.7326/0003-4819-38-3-433">Publisher Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d70223e3980 class=n-a></a>Stasi R, Pagano A, Stipa E, <i> et al.</i>: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. <i>Blood.</i> 2001; <b>98</b>(4): 952–7. <a target=xrefwindow id=d70223e3991 href="http://www.ncbi.nlm.nih.gov/pubmed/11493438">PubMed Abstract </a> | <a target=xrefwindow id=d70223e3994 href="http://dx.doi.org/10.1182/blood.V98.4.952">Publisher Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d70223e4003 class=n-a></a>Arnold DM, Dentali F, Crowther MA, <i> et al.</i>: Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. <i>Ann Intern Med.</i> 2007; <b>146</b>(1): 25–33. <a target=xrefwindow id=d70223e4014 href="http://www.ncbi.nlm.nih.gov/pubmed/17200219">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4017 href="http://dx.doi.org/10.7326/0003-4819-146-1-200701020-00006">Publisher Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717965659"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e4026 class=n-a></a>Patel VL, Mahévas M, Lee SY, <i> et al.</i>: Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. <i>Blood.</i> 2012; <b>119</b>(25): 5989–95. <a target=xrefwindow id=d70223e4037 href="http://www.ncbi.nlm.nih.gov/pubmed/22566601">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4040 href="http://dx.doi.org/10.1182/blood-2011-11-393975">Publisher Full Text </a> | <a target=xrefwindow id=d70223e4044 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3383014">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717965659">F1000 Recommendation</a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727195786"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e4057 class=n-a></a>Reboursiere E, Fouques H, Maigne G, <i> et al.</i>: Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles. <i>Int J Hematol.</i> 2016; <b>104</b>(1): 85–91. <a target=xrefwindow id=d70223e4068 href="http://www.ncbi.nlm.nih.gov/pubmed/27040278">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4071 href="http://dx.doi.org/10.1007/s12185-016-1992-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727195786">F1000 Recommendation</a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725347054"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e4084 class=n-a></a>Ghanima W, Khelif A, Waage A, <i> et al.</i>: Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet.</i> 2015; <b>385</b>(9978): 1653–61. <a target=xrefwindow id=d70223e4095 href="http://www.ncbi.nlm.nih.gov/pubmed/25662413">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4098 href="http://dx.doi.org/10.1016/S0140-6736(14)61495-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725347054">F1000 Recommendation</a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d70223e4111 class=n-a></a>Arnold DM, Heddle NM, Carruthers J, <i> et al.</i>: A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. <i>Blood.</i> 2012; <b>119</b>(6): 1356–62. <a target=xrefwindow id=d70223e4122 href="http://www.ncbi.nlm.nih.gov/pubmed/22223819">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4125 href="http://dx.doi.org/10.1182/blood-2011-08-374777">Publisher Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d70223e4135 class=n-a></a>Li Z, Mou W, Lu G, <i> et al.</i>: Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. <i>Int J Hematol.</i> 2011; <b>93</b>(1): 91–8. <a target=xrefwindow id=d70223e4146 href="http://www.ncbi.nlm.nih.gov/pubmed/21188563">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4149 href="http://dx.doi.org/10.1007/s12185-010-0753-z">Publisher Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717976348"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e4158 class=n-a></a>Gudbrandsdottir S, Birgens HS, Frederiksen H, <i> et al.</i>: Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. <i>Blood.</i> 2013; <b>121</b>(11): 1976–81. <a target=xrefwindow id=d70223e4169 href="http://www.ncbi.nlm.nih.gov/pubmed/23293082">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4172 href="http://dx.doi.org/10.1182/blood-2012-09-455691">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717976348">F1000 Recommendation</a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718390801"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e4185 class=n-a></a>Zaja F, Baccarani M, Mazza P, <i> et al.</i>: Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. <i>Blood.</i> 2010; <b>115</b>(14): 2755–62. <a target=xrefwindow id=d70223e4196 href="http://www.ncbi.nlm.nih.gov/pubmed/20130241">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4199 href="http://dx.doi.org/10.1182/blood-2009-07-229815">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718390801">F1000 Recommendation</a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d70223e4212 class=n-a></a>Choi PY, Roncolato F, Badoux X, <i> et al.</i>: A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). <i>Blood.</i> 2015; <b>126</b>(4): 500–3. <a target=xrefwindow id=d70223e4223 href="http://www.ncbi.nlm.nih.gov/pubmed/25972158">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4226 href="http://dx.doi.org/10.1182/blood-2015-03-631937">Publisher Full Text </a> | <a target=xrefwindow id=d70223e4230 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4560338">Free Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725308841"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e4239 class=n-a></a>Zhou H, Xu M, Qin P, <i> et al.</i>: A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. <i>Blood.</i> 2015; <b>125</b>(10): 1541–7. <a target=xrefwindow id=d70223e4250 href="http://www.ncbi.nlm.nih.gov/pubmed/25575541">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4253 href="http://dx.doi.org/10.1182/blood-2014-06-581868">Publisher Full Text </a> | <a target=xrefwindow id=d70223e4257 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4351949">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725308841">F1000 Recommendation</a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d70223e4270 class=n-a></a>Jaffe CJ, Atkinson JP, Frank MM: The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. <i>J Clin Invest.</i> 1976; <b>58</b>(4): 942–9. <a target=xrefwindow id=d70223e4278 href="http://www.ncbi.nlm.nih.gov/pubmed/965497">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4281 href="http://dx.doi.org/10.1172/JCI108547">Publisher Full Text </a> | <a target=xrefwindow id=d70223e4284 href="http://www.ncbi.nlm.nih.gov/pmc/articles/333257">Free Full Text </a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a name=d70223e4294 class=n-a></a>Jandl JH, Jones AR, Castle WB: The destruction of red cells by antibodies in man. I. Observations of the sequestration and lysis of red cells altered by immune mechanisms. <i>J Clin Invest.</i> 1957; <b>36</b>(10): 1428–59. <a target=xrefwindow id=d70223e4302 href="http://www.ncbi.nlm.nih.gov/pubmed/13475483">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4305 href="http://dx.doi.org/10.1172/JCI103542">Publisher Full Text </a> | <a target=xrefwindow id=d70223e4308 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1072745">Free Full Text </a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d70223e4317 class=n-a></a>Atkinson JP, Frank MM: Studies on the <i>in vivo</i> effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. <i>J Clin Invest.</i> 1974; <b>54</b>(2): 339–48. <a target=xrefwindow id=d70223e4328 href="http://www.ncbi.nlm.nih.gov/pubmed/4847248">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4331 href="http://dx.doi.org/10.1172/JCI107769">Publisher Full Text </a> | <a target=xrefwindow id=d70223e4335 href="http://www.ncbi.nlm.nih.gov/pmc/articles/301561">Free Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726682327"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e4344 class=n-a></a>Schwartz J, Padmanabhan A, Aqui N, <i> et al.</i>: Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. <i>J Clin Apher.</i> 2016; <b>31</b>(3): 149–62. <a target=xrefwindow id=d70223e4355 href="http://www.ncbi.nlm.nih.gov/pubmed/27322218">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4358 href="http://dx.doi.org/10.1002/jca.21470">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726682327">F1000 Recommendation</a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a name=d70223e4371 class=n-a></a>Geurs F, Ritter K, Mast A, <i> et al.</i>: Successful plasmapheresis in corticosteroid-resistant hemolysis in infectious mononucleosis: role of autoantibodies against triosephosphate isomerase. <i>Acta Haematol.</i> 1992; <b>88</b>(2–3): 142–6. <a target=xrefwindow id=d70223e4382 href="http://www.ncbi.nlm.nih.gov/pubmed/1466197">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4385 href="http://dx.doi.org/10.1159/000204671">Publisher Full Text </a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d70223e4394 class=n-a></a>Zoppi M, Oppliger R, Althaus U, <i> et al.</i>: Reduction of plasma cold agglutinin titers by means of plasmapheresis to prepare a patient for coronary bypass surgery. <i>Infusionsther Transfusionsmed.</i> 1993; <b>20</b>(1–2): 19–22. <a target=xrefwindow id=d70223e4405 href="http://www.ncbi.nlm.nih.gov/pubmed/8504237">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4408 href="http://dx.doi.org/10.1159/000222800">Publisher Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727195787"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e4417 class=n-a></a>Reynaud Q, Durieu I, Dutertre M, <i> et al.</i>: Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. <i>Autoimmun Rev.</i> 2015; <b>14</b>(4): 304–13. <a target=xrefwindow id=d70223e4428 href="http://www.ncbi.nlm.nih.gov/pubmed/25497766">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4431 href="http://dx.doi.org/10.1016/j.autrev.2014.11.014">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727195787">F1000 Recommendation</a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718088100"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e4445 class=n-a></a>Birgens H, Frederiksen H, Hasselbalch HC, <i> et al.</i>: A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. <i>Br J Haematol.</i> 2013; <b>163</b>(3): 393–9. <a target=xrefwindow id=d70223e4456 href="http://www.ncbi.nlm.nih.gov/pubmed/23981017">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4459 href="http://dx.doi.org/10.1111/bjh.12541">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718088100">F1000 Recommendation</a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d70223e4472 class=n-a></a>Turner N, Mason PJ, Brown R, <i> et al.</i>: Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen. <i>J Clin Invest.</i> 1992; <b>89</b>(2): 592–601. <a target=xrefwindow id=d70223e4483 href="http://www.ncbi.nlm.nih.gov/pubmed/1737849">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4486 href="http://dx.doi.org/10.1172/JCI115625">Publisher Full Text </a> | <a target=xrefwindow id=d70223e4490 href="http://www.ncbi.nlm.nih.gov/pmc/articles/442892">Free Full Text </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d70223e4499 class=n-a></a>Kalluri R, Wilson CB, Weber M, <i> et al.</i>: Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. <i>J Am Soc Nephrol.</i> 1995; <b>6</b>(4): 1178–85. <a target=xrefwindow id=d70223e4510 href="http://www.ncbi.nlm.nih.gov/pubmed/8589284">PubMed Abstract </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d70223e4519 class=n-a></a>Rutgers A, Meyers KE, Canziani G, <i> et al.</i>: High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients to alpha3(IV)NC1 collagen. <i>Kidney Int.</i> 2000; <b>58</b>(1): 115–22. <a target=xrefwindow id=d70223e4530 href="http://www.ncbi.nlm.nih.gov/pubmed/10886555">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4533 href="http://dx.doi.org/10.1046/j.1523-1755.2000.00146.x">Publisher Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d70223e4542 class=n-a></a>Sinico RA, Radice A, Corace C, <i> et al.</i>: Anti-glomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome: a comparison of different assays. <i>Nephrol Dial Transplant.</i> 2006; <b>21</b>(2): 397–401. <a target=xrefwindow id=d70223e4553 href="http://www.ncbi.nlm.nih.gov/pubmed/16234289">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4556 href="http://dx.doi.org/10.1093/ndt/gfi230">Publisher Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d70223e4565 class=n-a></a>Cui Z, Wang H, Zhao MH: Natural autoantibodies against glomerular basement membrane exist in normal human sera. <i>Kidney Int.</i> 2006; <b>69</b>(5): 894–9. <a target=xrefwindow id=d70223e4573 href="http://www.ncbi.nlm.nih.gov/pubmed/16518348">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4576 href="http://dx.doi.org/10.1038/sj.ki.5000135">Publisher Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d70223e4586 class=n-a></a>Lerner RA, Glassock RJ, Dixon FJ: The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. <i>J Exp Med.</i> 1967; <b>126</b>(6): 989–1004. <a target=xrefwindow id=d70223e4594 href="http://www.ncbi.nlm.nih.gov/pubmed/4964566">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4597 href="http://dx.doi.org/10.1084/jem.126.6.989">Publisher Full Text </a> | <a target=xrefwindow id=d70223e4600 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2138413">Free Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a name=d70223e4609 class=n-a></a>Lockwood CM, Boulton-Jones JM, Lowenthal RM, <i> et al.</i>: Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis. <i>Br Med J.</i> 1975; <b>2</b>(5965): 252–4. <a target=xrefwindow id=d70223e4620 href="http://www.ncbi.nlm.nih.gov/pubmed/1131574">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4623 href="http://dx.doi.org/10.1136/bmj.2.5965.252">Publisher Full Text </a> | <a target=xrefwindow id=d70223e4627 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1673280">Free Full Text </a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d70223e4636 class=n-a></a>Levy JB, Turner AN, Rees AJ, <i> et al.</i>: Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. <i>Ann Intern Med.</i> 2001; <b>134</b>(11): 1033–42. <a target=xrefwindow id=d70223e4647 href="http://www.ncbi.nlm.nih.gov/pubmed/11388816">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4650 href="http://dx.doi.org/10.7326/0003-4819-134-11-200106050-00009">Publisher Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725480895"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e4659 class=n-a></a>Touzot M, Poisson J, Faguer S, <i> et al.</i>: Rituximab in anti-GBM disease: A retrospective study of 8 patients. <i>J Autoimmun.</i> 2015; <b>60</b>: 74–9. <a target=xrefwindow id=d70223e4670 href="http://www.ncbi.nlm.nih.gov/pubmed/25953709">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4673 href="http://dx.doi.org/10.1016/j.jaut.2015.04.003">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725480895">F1000 Recommendation</a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d70223e4686 class=n-a></a>Motomura M, Johnston I, Lang B, <i> et al.</i>: An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. <i>J Neurol Neurosurg Psychiatr.</i> 1995; <b>58</b>(1): 85–7. <a target=xrefwindow id=d70223e4697 href="http://www.ncbi.nlm.nih.gov/pubmed/7823075">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4700 href="http://dx.doi.org/10.1136/jnnp.58.1.85">Publisher Full Text </a> | <a target=xrefwindow id=d70223e4704 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1073275">Free Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a name=d70223e4713 class=n-a></a>Nakao YK, Motomura M, Fukudome T, <i> et al.</i>: Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. <i>Neurology.</i> 2002; <b>59</b>(11): 1773–5. <a target=xrefwindow id=d70223e4724 href="http://www.ncbi.nlm.nih.gov/pubmed/12473768">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4727 href="http://dx.doi.org/10.1212/01.WNL.0000037485.56217.5F">Publisher Full Text </a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a name=d70223e4737 class=n-a></a>Lennon VA, Kryzer TJ, Griesmann GE, <i> et al.</i>: Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. <i>N Engl J Med.</i> 1995; <b>332</b>(22): 1467–74. <a target=xrefwindow id=d70223e4748 href="http://www.ncbi.nlm.nih.gov/pubmed/7739683">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4751 href="http://dx.doi.org/10.1056/NEJM199506013322203">Publisher Full Text </a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d70223e4760 class=n-a></a>Lang B, Newsom-Davis J, Wray D, <i> et al.</i>: Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. <i>Lancet.</i> 1981; <b>2</b>(8240): 224–6. <a target=xrefwindow id=d70223e4771 href="http://www.ncbi.nlm.nih.gov/pubmed/6114283">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4774 href="http://dx.doi.org/10.1016/S0140-6736(81)90474-8">Publisher Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a name=d70223e4783 class=n-a></a>Lang B, Newsom-Davis J, Prior C, <i> et al.</i>: Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. <i>J Physiol.</i> 1983; <b>344</b>: 335–45. <a target=xrefwindow id=d70223e4794 href="http://www.ncbi.nlm.nih.gov/pubmed/6655585">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4797 href="http://dx.doi.org/10.1113/jphysiol.1983.sp014943">Publisher Full Text </a> | <a target=xrefwindow id=d70223e4801 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1193844">Free Full Text </a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a name=d70223e4810 class=n-a></a>Fukunaga H, Engel AG, Lang B, <i> et al.</i>: Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. <i>Proc Natl Acad Sci U S A.</i> 1983; <b>80</b>(24): 7636–40. <a target=xrefwindow id=d70223e4821 href="http://www.ncbi.nlm.nih.gov/pubmed/6584877">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4824 href="http://dx.doi.org/10.1073/pnas.80.24.7636">Publisher Full Text </a> | <a target=xrefwindow id=d70223e4828 href="http://www.ncbi.nlm.nih.gov/pmc/articles/534395">Free Full Text </a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a name=d70223e4837 class=n-a></a>Lambert EH, Lennon VA: Selected IgG rapidly induces Lambert-Eaton myasthenic syndrome in mice: complement independence and EMG abnormalities. <i>Muscle Nerve.</i> 1988; <b>11</b>(11): 1133–45. <a target=xrefwindow id=d70223e4845 href="http://www.ncbi.nlm.nih.gov/pubmed/3226429">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4848 href="http://dx.doi.org/10.1002/mus.880111105">Publisher Full Text </a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a name=d70223e4857 class=n-a></a>Dau PC, Denys EH: Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. <i>Ann Neurol.</i> 1982; <b>11</b>(6): 570–5. <a target=xrefwindow id=d70223e4865 href="http://www.ncbi.nlm.nih.gov/pubmed/7114807">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4868 href="http://dx.doi.org/10.1002/ana.410110604">Publisher Full Text </a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a name=d70223e4878 class=n-a></a>Newsom-Davis J, Murray NM: Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. <i>Neurology.</i> 1984; <b>34</b>(4): 480–5. <a target=xrefwindow id=d70223e4886 href="http://www.ncbi.nlm.nih.gov/pubmed/6322050">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4889 href="http://dx.doi.org/10.1212/WNL.34.4.480">Publisher Full Text </a></span></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d70223e4898 class=n-a></a>Motomura M, Hamasaki S, Nakane S, <i> et al.</i>: Apheresis treatment in Lambert-Eaton myasthenic syndrome. <i>Ther Apher.</i> 2000; <b>4</b>(4): 287–90. <a target=xrefwindow id=d70223e4909 href="http://www.ncbi.nlm.nih.gov/pubmed/10975475">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4912 href="http://dx.doi.org/10.1046/j.1526-0968.2000.004004287.x">Publisher Full Text </a></span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a name=d70223e4921 class=n-a></a>Tim RW, Massey JM, Sanders DB: Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. <i>Neurology.</i> 2000; <b>54</b>(11): 2176–8. <a target=xrefwindow id=d70223e4929 href="http://www.ncbi.nlm.nih.gov/pubmed/10851390">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4932 href="http://dx.doi.org/10.1212/WNL.54.11.2176">Publisher Full Text </a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a name=d70223e4941 class=n-a></a>Pellkofer HL, Voltz R, Kuempfel T: Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. <i>Muscle Nerve.</i> 2009; <b>40</b>(2): 305–8. <a target=xrefwindow id=d70223e4949 href="http://www.ncbi.nlm.nih.gov/pubmed/19609921">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4952 href="http://dx.doi.org/10.1002/mus.21315">Publisher Full Text </a></span></li><li><a name=ref-160 class=n-a></a><span class=label>160. </span>&nbsp;<span class=citation><a name=d70223e4961 class=n-a></a>Maddison P, McConville J, Farrugia ME, <i> et al.</i>: The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. <i>J Neurol Neurosurg Psychiatry.</i> 2011; <b>82</b>(6): 671–3. <a target=xrefwindow id=d70223e4972 href="http://www.ncbi.nlm.nih.gov/pubmed/20392977">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4975 href="http://dx.doi.org/10.1136/jnnp.2009.197632">Publisher Full Text </a></span></li><li><a name=ref-161 class=n-a></a><span class=label>161. </span>&nbsp;<span class=citation><a name=d70223e4984 class=n-a></a>Woodley DT, Briggaman RA, O'Keefe EJ, <i> et al.</i>: Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. <i>N Engl J Med.</i> 1984; <b>310</b>(16): 1007–13. <a target=xrefwindow id=d70223e4995 href="http://www.ncbi.nlm.nih.gov/pubmed/6369131">PubMed Abstract </a> | <a target=xrefwindow id=d70223e4998 href="http://dx.doi.org/10.1056/NEJM198404193101602">Publisher Full Text </a></span></li><li><a name=ref-162 class=n-a></a><span class=label>162. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/10113956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e5008 class=n-a></a>Saleh MA, Ishii K, Kim Y, <i> et al.</i>: Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. <i>J Dermatol Sci.</i> 2011; <b>62</b>(3): 169–75. <a target=xrefwindow id=d70223e5019 href="http://www.ncbi.nlm.nih.gov/pubmed/21482078">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5022 href="http://dx.doi.org/10.1016/j.jdermsci.2011.03.003">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/10113956">F1000 Recommendation</a></span></li><li><a name=ref-163 class=n-a></a><span class=label>163. </span>&nbsp;<span class=citation><a name=d70223e5035 class=n-a></a>Kim JH, Kim YH, Kim S, <i> et al.</i>: Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions. <i>J Eur Acad Dermatol Venereol.</i> 2013; <b>27</b>(2): e224–30. <a target=xrefwindow id=d70223e5046 href="http://www.ncbi.nlm.nih.gov/pubmed/22731917">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5049 href="http://dx.doi.org/10.1111/j.1468-3083.2012.04617.x">Publisher Full Text </a></span></li><li><a name=ref-164 class=n-a></a><span class=label>164. </span>&nbsp;<span class=citation><a name=d70223e5058 class=n-a></a>Komorowski L, Muller R, Vorobyev A, <i> et al.</i>: Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. <i>J Am Acad Dermatol.</i> 2013; <b>68</b>(3): e89–95. <a target=xrefwindow id=d70223e5069 href="http://www.ncbi.nlm.nih.gov/pubmed/22341608">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5072 href="http://dx.doi.org/10.1016/j.jaad.2011.12.032">Publisher Full Text </a></span></li><li><a name=ref-165 class=n-a></a><span class=label>165. </span>&nbsp;<span class=citation><a name=d70223e5081 class=n-a></a>Terra JB, Jonkman MF, Diercks GF, <i> et al.</i>: Low sensitivity of type VII collagen enzyme-linked immunosorbent assay in epidermolysis bullosa acquisita: serration pattern analysis on skin biopsy is required for diagnosis. <i>Br J Dermatol.</i> 2013; <b>169</b>(1): 164–7. <a target=xrefwindow id=d70223e5092 href="http://www.ncbi.nlm.nih.gov/pubmed/23480491">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5095 href="http://dx.doi.org/10.1111/bjd.12300">Publisher Full Text </a></span></li><li><a name=ref-166 class=n-a></a><span class=label>166. </span>&nbsp;<span class=citation><a name=d70223e5104 class=n-a></a>Lee EH, Kim YH, Kim S, <i> et al.</i>: Usefulness of Enzyme-linked Immunosorbent Assay Using Recombinant BP180 and BP230 for Serodiagnosis and Monitoring Disease Activity of Bullous Pemphigoid. <i>Ann Dermatol.</i> 2012; <b>24</b>(1): 45–55. <a target=xrefwindow id=d70223e5115 href="http://www.ncbi.nlm.nih.gov/pubmed/22363155">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5118 href="http://dx.doi.org/10.5021/ad.2012.24.1.45">Publisher Full Text </a> | <a target=xrefwindow id=d70223e5122 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3283850">Free Full Text </a></span></li><li><a name=ref-167 class=n-a></a><span class=label>167. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725265022"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e5131 class=n-a></a>Esmaili N, Mortazavi H, Kamyab-Hesari K, <i> et al.</i>: Diagnostic accuracy of BP180 NC16a and BP230-C3 ELISA in serum and saliva of patients with bullous pemphigoid. <i>Clin Exp Dermatol.</i> 2015; <b>40</b>(3): 324–30. <a target=xrefwindow id=d70223e5142 href="http://www.ncbi.nlm.nih.gov/pubmed/25476471">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5145 href="http://dx.doi.org/10.1111/ced.12510">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725265022">F1000 Recommendation</a></span></li><li><a name=ref-168 class=n-a></a><span class=label>168. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/720896142"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e5159 class=n-a></a>Kobayashi M, Amagai M, Kuroda-Kinoshita K, <i> et al.</i>: BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. <i>J Dermatol Sci.</i> 2002; <b>30</b>(3): 224–32. <a target=xrefwindow id=d70223e5170 href="http://www.ncbi.nlm.nih.gov/pubmed/12443845">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5173 href="http://dx.doi.org/10.1016/S0923-1811(02)00109-3">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/720896142">F1000 Recommendation</a></span></li><li><a name=ref-169 class=n-a></a><span class=label>169. </span>&nbsp;<span class=citation><a name=d70223e5186 class=n-a></a>Zillikens D, Mascaro JM, Rose PA, <i> et al.</i>: A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. <i>J Invest Dermatol.</i> 1997; <b>109</b>(5): 679–83. <a target=xrefwindow id=d70223e5197 href="http://www.ncbi.nlm.nih.gov/pubmed/9347799">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5200 href="http://dx.doi.org/10.1111/1523-1747.ep12338088">Publisher Full Text </a></span></li><li><a name=ref-170 class=n-a></a><span class=label>170. </span>&nbsp;<span class=citation><a name=d70223e5209 class=n-a></a>Charneux J, Lorin J, Vitry F, <i> et al.</i>: Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. <i>Arch Dermatol.</i> 2011; <b>147</b>(3): 286–91. <a target=xrefwindow id=d70223e5220 href="http://www.ncbi.nlm.nih.gov/pubmed/21422334">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5223 href="http://dx.doi.org/10.1001/archdermatol.2011.23">Publisher Full Text </a></span></li><li><a name=ref-171 class=n-a></a><span class=label>171. </span>&nbsp;<span class=citation><a name=d70223e5232 class=n-a></a>Roussel A, Benichou J, Randriamanantany ZA, <i> et al.</i>: Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. <i>Arch Dermatol.</i> 2011; <b>147</b>(3): 293–8. <a target=xrefwindow id=d70223e5243 href="http://www.ncbi.nlm.nih.gov/pubmed/21422336">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5246 href="http://dx.doi.org/10.1001/archdermatol.2011.21">Publisher Full Text </a></span></li><li><a name=ref-172 class=n-a></a><span class=label>172. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/722427441"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e5255 class=n-a></a>van Beek N, Rentzsch K, Probst C, <i> et al.</i>: Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. <i>Orphanet J Rare Dis.</i> 2012; <b>7</b>: 49. <a target=xrefwindow id=d70223e5266 href="http://www.ncbi.nlm.nih.gov/pubmed/22876746">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5269 href="http://dx.doi.org/10.1186/1750-1172-7-49">Publisher Full Text </a> | <a target=xrefwindow id=d70223e5273 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3533694">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/722427441">F1000 Recommendation</a></span></li><li><a name=ref-173 class=n-a></a><span class=label>173. </span>&nbsp;<span class=citation><a name=d70223e5286 class=n-a></a>Schmidt E, Obe K, Brocker EB, <i> et al.</i>: Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. <i>Arch Dermatol.</i> 2000; <b>136</b>(2): 174–8. <a target=xrefwindow id=d70223e5297 href="http://www.ncbi.nlm.nih.gov/pubmed/10677092">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5300 href="http://dx.doi.org/10.1001/archderm.136.2.174">Publisher Full Text </a></span></li><li><a name=ref-174 class=n-a></a><span class=label>174. </span>&nbsp;<span class=citation><a name=d70223e5310 class=n-a></a>Sitaru C, Mihai S, Otto C, <i> et al.</i>: Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. <i>J Clin Invest.</i> 2005; <b>115</b>(4): 870–8. <a target=xrefwindow id=d70223e5321 href="http://www.ncbi.nlm.nih.gov/pubmed/15841176">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5324 href="http://dx.doi.org/10.1172/JCI21386">Publisher Full Text </a> | <a target=xrefwindow id=d70223e5328 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1070403">Free Full Text </a></span></li><li><a name=ref-175 class=n-a></a><span class=label>175. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/13453"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e5337 class=n-a></a>Woodley DT, Ram R, Doostan A, <i> et al.</i>: Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. <i>J Invest Dermatol.</i> 2006; <b>126</b>(6): 1323–30. <a target=xrefwindow id=d70223e5348 href="http://www.ncbi.nlm.nih.gov/pubmed/16543893">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5351 href="http://dx.doi.org/10.1038/sj.jid.5700254">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/13453">F1000 Recommendation</a></span></li><li><a name=ref-176 class=n-a></a><span class=label>176. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/6615957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e5364 class=n-a></a>Li Q, Ujiie H, Shibaki A, <i> et al.</i>: Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model. <i>J Immunol.</i> 2010; <b>185</b>(12): 7746–55. <a target=xrefwindow id=d70223e5375 href="http://www.ncbi.nlm.nih.gov/pubmed/21076071">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5378 href="http://dx.doi.org/10.4049/jimmunol.1000667">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/6615957">F1000 Recommendation</a></span></li><li><a name=ref-177 class=n-a></a><span class=label>177. </span>&nbsp;<span class=citation><a name=d70223e5391 class=n-a></a>Liu Z, Sui W, Zhao M, <i> et al.</i>: Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. <i>J Autoimmun.</i> 2008; <b>31</b>(4): 331–8. <a target=xrefwindow id=d70223e5402 href="http://www.ncbi.nlm.nih.gov/pubmed/18922680">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5405 href="http://dx.doi.org/10.1016/j.jaut.2008.08.009">Publisher Full Text </a> | <a target=xrefwindow id=d70223e5409 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2642586">Free Full Text </a></span></li><li><a name=ref-178 class=n-a></a><span class=label>178. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1433956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e5418 class=n-a></a>Wang G, Ujiie H, Shibaki A, <i> et al.</i>: Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigen. <i>Am J Pathol.</i> 2010; <b>176</b>(2): 914–25. <a target=xrefwindow id=d70223e5429 href="http://www.ncbi.nlm.nih.gov/pubmed/20042683">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5432 href="http://dx.doi.org/10.2353/ajpath.2010.090744">Publisher Full Text </a> | <a target=xrefwindow id=d70223e5436 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2808096">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1433956">F1000 Recommendation</a></span></li><li><a name=ref-179 class=n-a></a><span class=label>179. </span>&nbsp;<span class=citation><a name=d70223e5449 class=n-a></a>Niedermeier A, Eming R, Pfütze M, <i> et al.</i>: Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). <i>Arch Dermatol.</i> 2007; <b>143</b>(2): 192–8. <a target=xrefwindow id=d70223e5460 href="http://www.ncbi.nlm.nih.gov/pubmed/17309999">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5463 href="http://dx.doi.org/10.1001/archderm.143.2.192">Publisher Full Text </a></span></li><li><a name=ref-180 class=n-a></a><span class=label>180. </span>&nbsp;<span class=citation><a name=d70223e5473 class=n-a></a>Ino N, Kamata N, Matsuura C, <i> et al.</i>: Immunoadsorption for the treatment of bullous pemphigoid. <i>Ther Apher.</i> 1997; <b>1</b>(4): 372–6. <a target=xrefwindow id=d70223e5484 href="http://www.ncbi.nlm.nih.gov/pubmed/10225735">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5487 href="http://dx.doi.org/10.1111/j.1744-9987.1997.tb00059.x">Publisher Full Text </a></span></li><li><a name=ref-181 class=n-a></a><span class=label>181. </span>&nbsp;<span class=citation><a name=d70223e5496 class=n-a></a>Herrero-González JE, Sitaru C, Klinker E, <i> et al.</i>: Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption. <i>Clin Exp Dermatol.</i> 2005; <b>30</b>(5): 519–22. <a target=xrefwindow id=d70223e5507 href="http://www.ncbi.nlm.nih.gov/pubmed/16045683">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5510 href="http://dx.doi.org/10.1111/j.1365-2230.2005.01853.x">Publisher Full Text </a></span></li><li><a name=ref-182 class=n-a></a><span class=label>182. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727195789"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e5519 class=n-a></a>Kasperkiewicz M, Schulze F, Meier M, <i> et al.</i>: Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series. <i>J Am Acad Dermatol.</i> 2014; <b>71</b>(5): 1018–20. <a target=xrefwindow id=d70223e5530 href="http://www.ncbi.nlm.nih.gov/pubmed/25437968">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5533 href="http://dx.doi.org/10.1016/j.jaad.2014.06.014">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727195789">F1000 Recommendation</a></span></li><li><a name=ref-183 class=n-a></a><span class=label>183. </span>&nbsp;<span class=citation><a name=d70223e5546 class=n-a></a>Lourari S, Herve C, Doffoel-Hantz V, <i> et al.</i>: Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. <i>J Eur Acad Dermatol Venereol.</i> 2011; <b>25</b>(10): 1238–40. <a target=xrefwindow id=d70223e5557 href="http://www.ncbi.nlm.nih.gov/pubmed/21054575">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5560 href="http://dx.doi.org/10.1111/j.1468-3083.2010.03889.x">Publisher Full Text </a></span></li><li><a name=ref-184 class=n-a></a><span class=label>184. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/11732967"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e5569 class=n-a></a>Kasperkiewicz M, Shimanovich I, Ludwig RJ, <i> et al.</i>: Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. <i>J Am Acad Dermatol.</i> 2011; <b>65</b>(3): 552–8. <a target=xrefwindow id=d70223e5580 href="http://www.ncbi.nlm.nih.gov/pubmed/21641080">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5583 href="http://dx.doi.org/10.1016/j.jaad.2010.07.032">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/11732967">F1000 Recommendation</a></span></li><li><a name=ref-185 class=n-a></a><span class=label>185. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718097743"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e5596 class=n-a></a>Hall RP 3rd, Streilein RD, Hannah DL, <i> et al.</i>: Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. <i>J Invest Dermatol.</i> 2013; <b>133</b>(12): 2786–8. <a target=xrefwindow id=d70223e5607 href="http://www.ncbi.nlm.nih.gov/pubmed/23732750">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5610 href="http://dx.doi.org/10.1038/jid.2013.236">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718097743">F1000 Recommendation</a></span></li><li><a name=ref-186 class=n-a></a><span class=label>186. </span>&nbsp;<span class=citation><a name=d70223e5624 class=n-a></a>Ahmed AR, Shetty S, Kaveri S, <i> et al.</i>: Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up. <i>J Am Acad Dermatol.</i> 2016; <b>74</b>(4): 700–8.e3. <a target=xrefwindow id=d70223e5635 href="http://www.ncbi.nlm.nih.gov/pubmed/26851830">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5638 href="http://dx.doi.org/10.1016/j.jaad.2015.11.030">Publisher Full Text </a></span></li><li><a name=ref-187 class=n-a></a><span class=label>187. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725304668"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e5647 class=n-a></a>Cho YT, Chu CY, Wang LF: First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid. <i>Br J Dermatol.</i> 2015; <b>173</b>(1): 302–4. <a target=xrefwindow id=d70223e5655 href="http://www.ncbi.nlm.nih.gov/pubmed/25529394">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5658 href="http://dx.doi.org/10.1111/bjd.13633">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725304668">F1000 Recommendation</a></span></li><li><a name=ref-188 class=n-a></a><span class=label>188. </span>&nbsp;<span class=citation><a name=d70223e5671 class=n-a></a>Schmidt E, Benoit S, Bröcker E, <i> et al.</i>: Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. <i>Arch Dermatol.</i> 2006; <b>142</b>(2): 147–50. <a target=xrefwindow id=d70223e5682 href="http://www.ncbi.nlm.nih.gov/pubmed/16490841">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5685 href="http://dx.doi.org/10.1001/archderm.142.2.147">Publisher Full Text </a></span></li><li><a name=ref-189 class=n-a></a><span class=label>189. </span>&nbsp;<span class=citation><a name=d70223e5694 class=n-a></a>Crichlow SM, Mortimer NJ, Harman KE: A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. <i>Br J Dermatol.</i> 2007; <b>156</b>(1): 194–6. <a target=xrefwindow id=d70223e5702 href="http://www.ncbi.nlm.nih.gov/pubmed/17199602">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5705 href="http://dx.doi.org/10.1111/j.1365-2133.2006.07596.x">Publisher Full Text </a></span></li><li><a name=ref-190 class=n-a></a><span class=label>190. </span>&nbsp;<span class=citation><a name=d70223e5714 class=n-a></a>Sadler E, Schafleitner B, Lanschuetzer C, <i> et al.</i>: Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. <i>Br J Dermatol.</i> 2007; <b>157</b>(2): 417–9. <a target=xrefwindow id=d70223e5725 href="http://www.ncbi.nlm.nih.gov/pubmed/17596155">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5728 href="http://dx.doi.org/10.1111/j.1365-2133.2007.08048.x">Publisher Full Text </a></span></li><li><a name=ref-191 class=n-a></a><span class=label>191. </span>&nbsp;<span class=citation><a name=d70223e5737 class=n-a></a>Saha M, Cutler T, Bhogal B, <i> et al.</i>: Refractory epidermolysis bullosa acquisita: successful treatment with rituximab. <i>Clin Exp Dermatol.</i> 2009; <b>34</b>(8): e979–80. <a target=xrefwindow id=d70223e5748 href="http://www.ncbi.nlm.nih.gov/pubmed/20055876">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5751 href="http://dx.doi.org/10.1111/j.1365-2230.2009.03608.x">Publisher Full Text </a></span></li><li><a name=ref-192 class=n-a></a><span class=label>192. </span>&nbsp;<span class=citation><a name=d70223e5761 class=n-a></a>Kim JH, Lee SE, Kim SC: Successful treatment of epidermolysis bullosa acquisita with rituximab therapy. <i>J Dermatol.</i> 2012; <b>39</b>(5): 477–9. <a target=xrefwindow id=d70223e5769 href="http://www.ncbi.nlm.nih.gov/pubmed/22611565">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5772 href="http://dx.doi.org/10.1111/j.1346-8138.2011.01360.x">Publisher Full Text </a></span></li><li><a name=ref-193 class=n-a></a><span class=label>193. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718431247"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e5781 class=n-a></a>Iranzo P, Herrero-González JE, Mascaró-Galy JM, <i> et al.</i>: Epidermolysis bullosa acquisita: a retrospective analysis of 12 patients evaluated in four tertiary hospitals in Spain. <i>Br J Dermatol.</i> 2014; <b>171</b>(5): 1022–30. <a target=xrefwindow id=d70223e5792 href="http://www.ncbi.nlm.nih.gov/pubmed/24890437">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5795 href="http://dx.doi.org/10.1111/bjd.13144">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718431247">F1000 Recommendation</a></span></li><li><a name=ref-194 class=n-a></a><span class=label>194. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718843117"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d70223e5808 class=n-a></a>Kolesnik M, Becker E, Reinhold D, <i> et al.</i>: Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. <i>J Eur Acad Dermatol Venereol.</i> 2014; <b>28</b>(6): 771–80. <a target=xrefwindow id=d70223e5819 href="http://www.ncbi.nlm.nih.gov/pubmed/23651052">PubMed Abstract </a> | <a target=xrefwindow id=d70223e5822 href="http://dx.doi.org/10.1111/jdv.12175">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718843117">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 27 Jan 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-83/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-83/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Dermatology, University of Pennsylvania, 1009 Biomedical Research Building, 421 Curie Boulevard, PA, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-83/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 27 Jan 2017, 6:83 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.9476.1">https://doi.org/10.12688/f1000research.9476.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Ran NA and Payne AS. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=10206 data-id=9476 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9476.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-83/v1/pdf?article_uuid=b7cb8313-e027-4e43-93a7-2af5086c93e8" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.9476.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Ran NA and Payne AS. Rituximab therapy in pemphigus and other autoantibody-mediated diseases [version 1; peer review: 3 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):83 (<a href="https://doi.org/10.12688/f1000research.9476.1" target=_blank>https://doi.org/10.12688/f1000research.9476.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=9476 id=mobile-track-article-signin-9476 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9476?target=/articles/6-83/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10206 /> <input name=articleId type=hidden value=9476 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Dario Roccatello</strong>, Nephrology and Dialysis Unit, Center of Research of Immunopathology and Rare Diseases, Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Giovanni Bosco Hospital and University of Turin, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Marcel Jonkman</strong>, Department of Dermatology and Centre for Blistering Diseases, University Medical Centre Groningen, The Netherlands </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Enno Schmidt</strong>, Department of Dermatology, Allergy, and Venereology, University of Lübeck, Germany </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 27 Jan 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-83/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-83/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=20008-19669></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=20005-19667></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=20006-19668></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-83/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>27 Jan 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Dario Roccatello</strong>, Nephrology and Dialysis Unit, Center of Research of Immunopathology and Rare Diseases, Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Giovanni Bosco Hospital and University of Turin, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Marcel Jonkman</strong>, Department of Dermatology and Centre for Blistering Diseases, University Medical Centre Groningen, The Netherlands </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Enno Schmidt</strong>, Department of Dermatology, Allergy, and Venereology, University of Lübeck, Germany </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-83/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-83/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Rituximab therapy in pemphigus and other...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-83/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-83/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-83/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Ran NA and Payne AS');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-83/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-83",
            templates : {
                twitter : "Rituximab therapy in pemphigus and other autoantibody-mediated.... Ran NA and Payne AS, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-83/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Rituximab therapy in pemphigus and other autoantibody-mediated diseases", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Rituximab therapy in pemphigus and other autoantibody-mediated diseases", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/9476/10206")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "10206");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "19667": 0,
                           "19668": 0,
                           "19669": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "f50c4dc6-e2d2-4f2a-aa33-458cba4d7b52";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-83.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-83.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-83.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-83.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-83.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>